U.S. patent application number 10/451105 was filed with the patent office on 2004-04-01 for pharmacuetical formulation comprising puyrazolo[4,-3-d]pyrimidines and antithrombotics, calcium antagonists, or prostaglandins or prostaglandin derivatives.
Invention is credited to Eggenweiler, Hans-Michael, Eiermann, Volker.
Application Number | 20040063730 10/451105 |
Document ID | / |
Family ID | 27214208 |
Filed Date | 2004-04-01 |
United States Patent
Application |
20040063730 |
Kind Code |
A1 |
Eggenweiler, Hans-Michael ;
et al. |
April 1, 2004 |
Pharmacuetical formulation comprising puyrazolo[4,-3-d]pyrimidines
and antithrombotics, calcium antagonists, or prostaglandins or
prostaglandin derivatives
Abstract
The invention relates to a pharmaceutical preparation containing
at least one compound of formula (I), wherein R1, R2, R3, R4 and X
have the meanings as cited in claim No. 1, and to their
physiologically safe salts and/or solvates, and containing; a) at
least one antithrombotic agent or; b) at least one calcium
antagonist or; c) at least on prostaglandin or prostaglandin
derivative for producing a medicament used for treating angina,
hypertension, pulmonary hypertension, congestive heart failure
(CHF), chronic obstructive pulmonary disease (COPD), cor pulmonale,
right ventricular failure, atherosclerosis, conditions of reduced
patency of the heart vessels, peripheral vascular diseases,
cerebrovascular accident, bronchitis, allergic asthma, chronic
asthma, allergic rhinitis, glaucoma, irritable bowel syndrome,
tumors, kidney failure, cirrhosis of the liver, and for treating
female sexual dysfunctions. 1
Inventors: |
Eggenweiler, Hans-Michael;
(Darmstadt, DE) ; Eiermann, Volker; (Rodermark,
DE) |
Correspondence
Address: |
Millen White
Zelano & Branigan
Arlington Courthouse Plaza I
2200 Clarendon Boulevard Suite 1400
Arlington
VA
22201
US
|
Family ID: |
27214208 |
Appl. No.: |
10/451105 |
Filed: |
June 19, 2003 |
PCT Filed: |
November 28, 2001 |
PCT NO: |
PCT/EP01/13916 |
Current U.S.
Class: |
514/262.1 |
Current CPC
Class: |
A61P 9/08 20180101; A61P
1/04 20180101; A61P 35/00 20180101; A61P 27/06 20180101; A61K 45/06
20130101; A61P 9/10 20180101; A61P 11/06 20180101; A61P 11/02
20180101; A61K 31/519 20130101; A61P 9/04 20180101; A61P 9/12
20180101; A61P 13/12 20180101; A61P 15/10 20180101; A61P 39/00
20180101; A61P 1/16 20180101; A61P 37/08 20180101; A61P 11/00
20180101; A61K 31/519 20130101; A61K 2300/00 20130101 |
Class at
Publication: |
514/262.1 |
International
Class: |
A61K 031/519 |
Foreign Application Data
Date |
Code |
Application Number |
Dec 19, 2000 |
DE |
100 63 224.6 |
Dec 21, 2000 |
DE |
100 63 882.1 |
Dec 23, 2000 |
DE |
100 64 993.9 |
Claims
1. Pharmaceutical formulation comprising at least one
phosphodiesterase V inhibitor and/or physiologically acceptable
salts and/or solvates thereof and at least one antithrombotic.
2. Pharmaceutical formulation comprising at least one compound of
the formula I 53in which R.sup.1 and R.sup.2 are each,
independently of one another, H, A, OH, OA or Hal, R.sup.1 and
R.sup.2 together are alternatively alkylene having 3-5 carbon
atoms, --O--CH.sub.2--CH.sub.2--- , --CH.sub.2--O--CH.sub.2--,
--O--CH.sub.2--O-- or --O--CH.sub.2--CH.sub.2- --O--, R.sup.3 and
R.sup.4 are each, independently of one another, H or A, X is
R.sup.5, R.sup.6 or R.sup.7 which is monosubstituted by R.sup.8,
R.sup.5 is linear or branched alkylene having 1-10 carbon atoms, in
which one or two CH.sub.2 groups may be replaced by --CH.dbd.CH--
groups, O, S or SO, R.sup.6 is cycloalkyl or cycloalkylalkylene
having 5-12 carbon atoms, R.sup.7 is phenyl or phenylmethyl,
R.sup.8 is COOH, COOA, CONH.sub.2, CONHA, CON(A).sub.2 or CN, A is
alkyl having from 1 to 6 carbon atoms, and Hal is F, Cl, Br or I,
and/or physiologically acceptable salts and/or solvates thereof and
a) at least one antithrombotic or b) at least one calcium
antagonist or c) at least one prostaglandin or prostaglandin
derivative.
3. Pharmaceutical formulation according to claim 2, comprising at
least one compound of the formula I 54in which R.sup.1 and R.sup.2
are each, independently of one another, H, A, OH, OA or Hal,
R.sup.1 and R.sup.2 together are alternatively alkylene having 3-5
carbon atoms, --O--CH.sub.2--CH.sub.2--, --CH.sub.2--O--CH.sub.2--,
--O--CH.sub.2--O-- or --O--CH.sub.2--CH.sub.2--O--, R.sup.3 and
R.sup.4 are each, independently of one another, H or A, X is
R.sup.5, R.sup.6 or R.sup.7 which is monosubstituted by R.sup.8,
R.sup.5 is linear or branched alkylene having 1-10 carbon atoms, in
which one or two CH.sub.2 groups may be replaced by --CH.dbd.CH--
groups, O, S or SO, R.sup.6 is cycloalkyl or cycloalkylalkylene
having 5-12 carbon atoms, R.sup.7 is phenyl or phenylmethyl,
R.sup.8 is COOH, COOA, CONH.sub.2, CONHA, CON(A).sub.2 or CN, A is
alkyl having from 1 to 6 carbon atoms, and Hal is F, Cl, Br or I,
and/or physiologically acceptable salts and/or solvates thereof and
at least one antithrombotic.
4. Pharmaceutical formulation according to claim 3, comprising at
least one compound of the formula I according to claim 3 in which X
is R.sup.5, phenyl or phenylmethyl, each of which is substituted by
COOH, COOA, CONH.sub.2, CONA.sub.2, CONHA or CN; and/or
physiologically acceptable salts and/or solvates thereof and at
least one antithrombotic.
5. Pharmaceutical formulation according to claim 3, comprising at
least one compound of the formula I according to claim 3 in which
R.sup.1 and R.sup.2 together are alkylene having 3-5 carbon atoms,
--O--CH.sub.2--CH.sub.2--, --O--CH.sub.2--O-- or
--O--CH.sub.2--CH.sub.2-- -O--, X is R.sup.5, phenyl or
phenylmethyl, each of which is substituted by COOH, COOA,
CONH.sub.2, CONA.sub.2, CONHA or CN; and/or physiologically
acceptable salts and/or solvates thereof and at least one
antithrombotic.
6. Pharmaceutical formulation according to claim 3, comprising at
least one compound of the formula I according to claim 3 in which
R.sup.1 and R.sup.2 are each, independently of one another, H, A,
OH, OA or Hal, R.sup.1 and R.sup.2 together are alternatively
alkylene having 3-5 carbon atoms, --O--CH.sub.2--CH.sub.2--,
--O--CH.sub.2--O-- or --O--CH.sub.2--CH.sub.2--O--, X is R.sup.5,
phenyl or phenylmethyl, each of which is substituted by COOH, COOA,
CONH.sub.2, CONA.sub.2, CONHA or CN; and/or physiologically
acceptable salts and/or solvates thereof and at least one
antithrombotic.
7. Pharmaceutical formulation according to claim 3, comprising at
least one compound of the formula I according to claim 3 in which
R.sup.1 and R.sup.2 are each, independently of one another, H, A,
OH, OA or Hal, R.sup.1 and R.sup.2 together are alternatively
alkylene having 3-5 carbon atoms, --O--CH.sub.2--CH.sub.2--,
--O--CH.sub.2--O-- or --O--CH.sub.2--CH.sub.2--O--, X is alkylene
having 2-5 carbon atoms, cyclohexyl, phenyl or phenylmethyl, each
of which is monosubstituted by R.sup.8, R.sup.3 is alkyl having 1-6
carbon atoms, R.sup.4 is alkyl having 1-6 carbon atoms, R.sup.8 is
COOH or COOA, A is alkyl having from 1 to 6 carbon atoms, Hal is F,
Cl, Br or I; and/or physiologically acceptable salts and/or
solvates thereof and at least one antithrombotic.
8. Pharmaceutical formulation according to claim 3, comprising at
least one compound of the formula I according to claim 3 in which
R.sup.1 and R.sup.2 are each, independently of one another, H, A,
OH, OA or Hal, R.sup.1 and R.sup.2 together are alternatively
alkylene having 3-5 carbon atoms, --O--CH.sub.2--CH.sub.2--,
--O--CH.sub.2--O-- or --O--CH.sub.2--CH.sub.2--O--, R.sup.3 is
alkyl having 1-6 carbon atoms, R.sup.4 is alkyl having 1-6 carbon
atoms, X is --(CH.sub.2).sub.2-5--R.su- p.8, in which one CH.sub.2
group may be replaced by O, or is 4-R.sup.8-cyclohexyl,
4-R.sup.8-phenyl or 4-(R.sup.8-methyl)phenyl, R.sup.8 is COOH or
COOA; and/or physiologically acceptable salts and/or solvates
thereof and at least one antithrombotic.
9. Pharmaceutical formulation according to claim 3, comprising at
least one compound of the formula I according to claim 3 selected
from the group consisting of (a)
5-[7-(3-chloro-4-methoxybenzylamino-1-methyl-3-pr- opyl-1
H-pyrazolo[4,3-d]pyrimidin-5-yl]pentanoic acid; (b)
4-[7-(3-chloro-4-methoxybenzylamino)1-methyl-3-propyl-1H-pyrazolo[4,3-d]p-
yrimidin-5-yl]benzoic acid; (c)
4-[7-(3,4-methylenedioxybenzylamino)1-meth-
yl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]butyric acid; (d)
5-[7-(benzylamino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]-pyrimidin-5-yl]pe-
ntanoic acid; (e)
[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1H--
pyrazolo[4,3-d]pyrimidin-5-ylmethoxy]acetic acid and/or
physiologically acceptable salts and/or solvates thereof and at
least one antithrombotic.
10. Pharmaceutical formulation according to claim 9, comprising at
least
[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo-[4,3-d]p-
yrimidin-5-ylmethoxy]acetic acid, ethanolamine salt, and at least
one antithrombotic.
11. Pharmaceutical formulation according to claims 1 to 10, in
which the antithrombotic is selected from the group consisting of
vitamin K antagonists, heparin compounds, thrombocyte aggregation
inhibitors, enzymes, factor Xa inhibitors, factor VIIa inhibitors
and other antithrombotic agents.
12. Pharmaceutical formulation according to claim 11, where the
vitamin K antagonists are selected from the group consisting of
dicoumarol, phenindione, warfarin, phenprocoumon, acenocoumarol,
ethyl biscoumacetate, clorindione, diphenadione and
tioclomarol.
13. Pharmaceutical formulation according to claim 11, where the
heparin compounds are selected from the group consisting of
heparin, antithrombin III, dalteparin, enoxaparin, nadroparin,
parnaparin, reviparin, danaparoid, tinzaparin and sulodexide.
14. Pharmaceutical formulation according to claim 11, where the
thrombocyte aggregation inhibitors are selected from the group
consisting of ditazole, cloricromen, picotamide, clopidogrel,
ticlopidine, acetylsalicylic acid, dipyridamole, calcium
carbassalate, epoprostenol, indobufen, iloprost, abciximab,
tirofiban, aloxiprin and intrifiban.
15. Pharmaceutical formulation according to claim 11, where the
enzymes are selected from the group consisting of streptokinase,
alteplase, anistreplase, urokinase, fibrinolysin, brinase,
reteplase and saruplase.
16. Pharmaceutical formulation according to claim 11, where other
antithrombotic agents are selected from the group consisting of
defibrotide, desirudin and lepirudin.
17. Pharmaceutical formulation according to claims 1-10, where the
antithrombotic is selected from the group consisting of blood
platelet glycoprotein receptor (IIb/IIIa) antagonists.
18. Pharmaceutical formulation according to claim 2, comprising at
least one compound of the formula I 55in which R.sup.1 and R.sup.2
are each, independently of one another, H, A, OH, OA or Hal,
R.sup.1 and R.sup.2 together are alternatively alkylene having 3-5
carbon atoms, --O--CH.sub.2--CH.sub.2--, --CH.sub.2--O--CH.sub.2--,
--O--CH.sub.2--O-- or --O--CH.sub.2--CH.sub.2--O--, R.sup.3 and
R.sup.4 are each, independently of one another, H or A, X is
R.sup.5, R.sup.6 or R.sup.7, each of which is monosubstituted by
R.sup.8, R.sup.5 is linear or branched alkylene having 1-10 carbon
atoms, in which one or two CH.sub.2 groups may be replaced by
--CH.dbd.CH-- groups, O, S or SO, R.sup.6 is cycloalkyl or
cycloalkylalkylene having 5-12 carbon atoms, R.sup.7 is phenyl or
phenylmethyl, R.sup.8 is COOH, COOA, CONH.sub.2, CONHA,
CON(A).sub.2 or CN, A is alkyl having from 1 to 6 carbon atoms, and
Hal is F, Cl, Br or I, and/or physiologically acceptable salts
and/or solvates thereof and at least one calcium antagonist.
19. Pharmaceutical formulation according to claim 18, comprising at
least one compound of the formula I according to claim 18 in which
X is R.sup.5, phenyl or phenylmethyl, each of which is substituted
by COOH, COOA, CONH.sub.2, CONA.sub.2, CONHA or CN; and/or
physiologically acceptable salts and/or solvates thereof and at
least one calcium antagonist.
20. Pharmaceutical formulation according to claim 18, comprising at
least one compound of the formula I according to claim 18 in which
R.sup.1 and R.sup.2 together are alkylene having 3-5 carbon atoms,
--O--CH.sub.2--CH.sub.2--, --O--CH.sub.2--O-- or
--O--CH.sub.2--CH.sub.2-- -O--, X is R.sup.5, phenyl or
phenylmethyl, each of which is substituted by COOH, COOA,
CONH.sub.2, CONA.sub.2, CONHA or CN; and/or physiologically
acceptable salts and/or solvates thereof and at least one calcium
antagonist.
21. Pharmaceutical formulation according to claim 18, comprising at
least one compound of the formula I according to claim 18 in which
R.sup.1 and R.sup.2 are each, independently of one another, H, A,
OH, OA or Hal, R.sup.1 and R.sup.2 together are alternatively
alkylene having 3-5 carbon atoms, --O--CH.sub.2--CH.sub.2--,
--O--CH.sub.2--O-- or --O--CH.sub.2--CH.sub.2--O--, X is R.sup.5,
phenyl or phenylmethyl, each of which is substituted by COOH, COOA,
CONH.sub.2, CONA.sub.2, CONHA or CN; and/or physiologically
acceptable salts and/or solvates thereof and at least one calcium
antagonist.
22. Pharmaceutical formulation according to claim 18, comprising at
least one compound of the formula I according to claim 18 in which
R.sup.1 and R.sup.2 are each, independently of one another, H, A,
OH, OA or Hal, R.sup.1 and R.sup.2 together are alternatively
alkylene having 3-5 carbon atoms, --O--CH.sub.2--CH.sub.2--,
--O--CH.sub.2--O-- or --O--CH.sub.2--CH.sub.2--O--, X is alkylene
having 2-5 carbon atoms, cyclohexyl, phenyl or phenylmethyl, each
of which is monosubstituted by R.sup.8, R.sup.3 is alkyl having 1-6
carbon atoms, R.sup.4 is alkyl having 1-6 carbon atoms, R.sup.8 is
COOH or COOA, A is alkyl having from 1 to 6 carbon atoms, Hal is F,
Cl, Br or I; and/or physiologically acceptable salts and/or
solvates thereof and at least one calcium antagonist.
23. Pharmaceutical formulation according to claim 18, comprising at
least one compound of the formula I according to claim 18 in which
R.sup.1 and R.sup.2 are each, independently of one another, H, A,
OH, OA or Hal, R.sup.1 and R.sup.2 together are alternatively
alkylene having 3-5 carbon atoms, --O--CH.sub.2--CH.sub.2--,
--O--CH.sub.2--O-- or --O--CH.sub.2--CH.sub.2--O--, R.sup.3 is
alkyl having 1-6 carbon atoms, R.sup.4 is alkyl having 1-6 carbon
atoms, x is --(CH.sub.2).sub.2-5--R.su- p.8, in which one CH.sub.2
group may be replaced by 0, or is 4-R.sup.8-cyclohexyl,
4-R.sup.8-phenyl or 4-(R.sup.8-methyl)phenyl, R.sup.8 is COOH or
COOA; and/or physiologically acceptable salts and/or solvates
thereof and at least one calcium antagonist.
24. Pharmaceutical formulation according to claim 18, comprising at
least one compound of the formula I according to claim 18 selected
from the group consisting of (a)
5-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-p-
ropyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]pentanoic acid; (b)
4-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]-
pyrimidin-5-yl]benzoic acid; (c)
4-[7-(3,4-methylenedioxybenzylamino)-1-me- thyl-3-propyl-1
H-pyrazolo[4,3-d]pyrimidin-5-yl]butyric acid; (d)
5-[7-(benzylamino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]-pyrimidin-5-yl]pe-
ntanoic acid; (e)
[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1H--
pyrazolo[4,3-d]pyrimidin-5-ylmethoxy]acetic acid and/or
physiologically acceptable salts and/or solvates thereof and at
least one calcium antagonist.
25. Pharmaceutical formulation according to claim 24, comprising at
least
[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]py-
rimidin-5-ylmethoxy]acetic acid, ethanolamine salt, and at least
one calcium antagonist.
26. Pharmaceutical formulation according to claims 2 and 18 to 25,
in which the calcium antagonist is selected from the group
consisting of selective and non-selective calcium antagonists.
27. Pharmaceutical formulation according to claim 26, in which the
selective calcium antagonists are selected from the group
consisting of dihydropyridine derivatives, phenylalkylamine
derivatives, benzothiazepine derivatives and other selective
calcium antagonists.
28. Pharmaceutical formulation according to claim 27, in which the
dihydropyridine derivatives are selected from the group consisting
of amlodipine, felodipine, isradipine, nicardipine, nifedipine,
nimodipine, nisoldipine, nitrendipine, lacidipine, nilvadipine,
manidipine, bamidipine and lercanidipine.
29. Pharmaceutical formulation according to claim 27, in which the
phenylalkylamine derivatives are selected from the group consisting
of verapamil and gallopamil.
30. Pharmaceutical formulation according to claim 27, in which the
benzothiazepine derivative is diltiazem.
31. Pharmaceutical formulation according to claim 27, in which the
other selective calcium antagonist is mibefradil.
32. Pharmaceutical formulation according to claim 26, in which the
nonselective calcium antagonists are selected from the group
consisting of fendiline, bepridil, lidoflazine and perhexiline.
33. Pharmaceutical formulation according to claim 2, comprising at
least one compound of the formula I 56in which R.sup.1 and R.sup.2
are each, independently of one another, H, A, OH, OA or Hal,
R.sup.1 and R.sup.2 together are alternatively alkylene having 3-5
carbon atoms, --O--CH.sub.2--CH.sub.2--, --CH.sub.2--O--CH.sub.2--,
--O--CH.sub.2--O-- or --O--CH.sub.2--CH.sub.2--O--, R.sup.3 and
R.sup.4 are each, independently of one another, H or A, X is
R.sup.5, R.sup.6 or R.sup.7, each of which is monosubstituted by
R.sup.8, R.sup.5 is linear or branched alkylene having 1-10 carbon
atoms, in which one or two CH.sub.2 groups may be replaced by
--CH.dbd.CH-- groups, O, S or SO, R.sup.6 is cycloalkyl or
cycloalkylalkylene having 5-12 carbon atoms, R.sup.7 is phenyl or
phenylmethyl, R.sup.8 is COOH, COOA, CONH.sub.2, CONHA,
CON(A).sub.2 or CN, A is alkyl having from 1 to 6 carbon atoms, and
Hal is F, Cl, Br or I, and/or physiologically acceptable salts
and/or solvates thereof and at least one prostaglandin or
prostaglandin derivative.
34. Pharmaceutical formulation according to claim 33, comprising at
least one compound of the formula I according to claim 33 in which
X is R.sup.5, phenyl or phenylmethyl, each of which is substituted
by COOH, COOA, CONH.sub.2, CONA.sub.2, CONHA or CN; and/or
physiologically acceptable salts and/or solvates thereof and at
least one prostaglandin or prostaglandin derivative.
35. Pharmaceutical formulation according to claim 33, comprising at
least one compound of the formula I according to claim 33 in which
R.sup.1 and R.sup.2 together are alkylene having 3-5 carbon atoms,
--O--CH.sub.2--CH.sub.2--, --O--CH.sub.2--O-- or
--O--CH.sub.2--CH.sub.2-- -O--, X is R.sup.5, phenyl or
phenylmethyl, each of which is substituted by COOH, COOA,
CONH.sub.2, CONA.sub.2, CONHA or CN; and/or physiologically
acceptable salts and/or solvates thereof and at least one
prostaglandin or prostaglandin derivative.
36. Pharmaceutical formulation according to claim 33, comprising at
least one compound of the formula I according to claim 33 in which
R.sup.1 and R.sup.2 are each, independently of one another, H, A,
OH, OA or Hal, R.sup.1 and R.sup.2 together are alternatively
alkylene having 3-5 carbon atoms, --O--CH.sub.2--CH.sub.2--,
--O--CH.sub.2--O-- or --O--CH.sub.2--CH.sub.2--O--, X is R.sup.5,
phenyl or phenylmethyl, each of which is substituted by COOH, COOA,
CONH.sub.2, CONA.sub.2, CONHA or CN; and/or physiologically
acceptable salts and/or solvates thereof and at least one
prostaglandin or prostaglandin derivative.
37. Pharmaceutical formulation according to claim 33, comprising at
least one compound of the formula I according to claim 33 in which
R.sup.1 and R.sup.2 are each, independently of one another, H, A,
OH, OA or Hal, R.sup.1 and R.sup.2 together are alternatively
alkylene having 3-5 carbon atoms, --O--CH.sub.2--CH.sub.2--,
--O--CH.sub.2--O-- or --O--CH.sub.2--CH.sub.2--O--, X is alkylene
having 2-5 carbon atoms, cyclohexyl, phenyl or phenylmethyl, each
of which is monosubstituted by R.sup.8, R.sup.3 is alkyl having 1-6
carbon atoms, R.sup.4 is alkyl having 1-6 carbon atoms, R.sup.8 is
COOH or COOA, A is alkyl having from 1 to 6 carbon atoms, Hal is F,
Cl, Br or I; and/or physiologically acceptable salts and/or
solvates thereof and at least one prostaglandin or prostaglandin
derivative.
38. Pharmaceutical formulation according to claim 33, comprising at
least one compound of the formula I according to claim 33 in which
R.sup.1 and R.sup.2 are each, independently of one another, H, A,
OH, OA or Hal, R.sup.1 and R.sup.2 together are alternatively
alkylene having 3-5 carbon atoms, --O--CH.sub.2--CH.sub.2--,
--O--CH.sub.2--O-- or --O--CH.sub.2--CH.sub.2--O--, R.sup.3 is
alkyl having 1-6 carbon atoms, R.sup.4 is alkyl having 1-6 carbon
atoms, X is --(CH.sub.2).sub.2-5--R.su- p.8, in which one CH.sub.2
group may be replaced by O, or is 4-R.sup.8-cyclohexyl,
4-R.sup.8-phenyl or 4-(R.sup.8-methyl)phenyl, R.sup.8 is COOH or
COOA; and/or physiologically acceptable salts and/or solvates
thereof and at least one prostaglandin or prostaglandin
derivative.
39. Pharmaceutical formulation according to claim 33, comprising at
least one compound of the formula I according to claim 33 selected
from the group consisting of (a)
5-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-p-
ropyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]pentanoic acid; (b)
4-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]-
pyrimidin-5-yl]benzoic acid; (c)
4-[7-(3,4-methylenedioxybenzylamino)-1-me-
thyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]butyric acid; (d)
5-[7-(benzylamino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]-pyrimidin-5-yl]pe-
ntanoic acid; (e)
[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1H--
pyrazolo[4,3-d]pyrimidin-5-ylmethoxy]acetic acid and/or
physiologically acceptable salts and/or solvates thereof and at
least one prostaglandin or prostaglandin derivative.
40. Pharmaceutical formulation according to claim 39, comprising at
least
[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]py-
rimidin-5-ylmethoxy]acetic acid, ethanolamine salt, and at least
one prostaglandin or prostaglandin derivative.
41. Pharmaceutical formulation according to claims 2 and 33 to 40,
in which the prostaglandin or prostaglandin derivative is selected
from the group consisting of alprostadil (PGE.sub.1), dinoprost
(PGF.sub.2), dinoprostone (PGE.sub.2), epoprostenol sodium
(PGI.sub.2; prostacyclin sodium), gemeprost, iloprost, latanoprost,
misoprostol, sulprostone, carboprost, thromethamin, dinoprost
thromethamin, lipoprost, metenoprost and tiaprost.
42. Pharmaceutical formulation according to claim 41, in which the
prostaglandin is PGE.sub.1 or prostacyclin.
43. Pharmaceutical formulation according to claim 41, in which the
prostaglandin is prostacyclin.
44. Pharmaceutical formation according to one of the preceding
claims, comprising one or more excipients and/or assistants.
45. Use of a pharmaceutical preparation according to one of claims
1 to 44 for the preparation of a medicament for the treatment of
angina, high blood pressure, pulmonary hypertension, congestive
heart failure (CHF), chronic obstructive pulmonary disease (COPD),
cor pulmonale, dextrocardiac insufficiency, atherosclerosis,
conditions of reduced patency of heart vessels, peripheral vascular
diseases, strokes, bronchitis, allergic asthma, chronic asthma,
allergic rhinitis, glaucoma, irritable bowel syndrome, tumours,
renal insufficiency, liver cirrhosis and for the treatment of
female sexual disorders.
46. Use according to claim 45 for the preparation of a medicament
for the treatment of pulmonary hypertension, congestive heart
failure (CHF), chronic obstructive pulmonary disease (COPD), cor
pulmonale and/or dextrocardiac insufficiency.
47. Set (kit) consisting of separate packs of (a) an effective
amount
[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]py-
rimidin-5-ylmethoxy]acetic acid, ethanolamine salt, and (b) an
effective amount of an antithrombotic.
48. Use of
[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1H-pyrazol-
o[4,3-d]pyrimidin-5-ylmethoxy]acetic acid, ethanolamine salt, for
the preparation of a medicament for the treatment of pulmonary
hypertension, congestive heart failure (CHF), chronic obstructive
pulmonary disease (COPD), cor pulmonale and/or dextrocardiac
insufficiency.
49. Set (kit) consisting of separate packs of (a) an effective
amount of
[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]py-
rimidin-5-ylmethoxy]acetic acid, ethanolamine salt, and (b) an
effective amount of a calcium antagonist.
50. Set (kit) consisting of separate packs of (a) an effective
amount of
[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]py-
rimidin-5-ylmethoxy]acetic acid, ethanolamine salt, and (b) an
effective amount of a prostaglandin or prostaglandin
derivative.
51. Use of a pharmaceutical preparation comprising at least one
phosphodiesterase V inhibitor and at least one prostaglandin or
prostaglandin derivative for the preparation of a medicament for
the oral treatment of pulmonary hypertension, congestive heart
failure (CHF), chronic obstructive pulmonary disease (COPD), cor
pulmonale and/or dextrocardiac insufficiency.
Description
[0001] The invention relates to pharmaceutical formulations
comprising at least one phosphodiesterase V inhibitor and/or
physiologically acceptable salts and/or solvates thereof and at
least one antithrombotic.
[0002] The invention relates in particular to pharmaceutical
formulations comprising at least one compound of the formula I
2
[0003] in which
[0004] R.sup.1 and R.sup.2 are each, independently of one another,
H, A, OH, OA or Hal,
[0005] R.sup.1 and R.sup.2 together are alternatively alkylene
having 3-5 carbon atoms, --O--CH.sub.2--CH.sub.2--,
--CH.sub.2--O--CH.sub.2--, --O--CH.sub.2--O-- or
--O--CH.sub.2--CH.sub.2--O--,
[0006] R.sup.3 and R.sup.4 are each, independently of one another,
H or A,
[0007] X is R.sup.5, R.sup.6 or R.sup.7, each of which is
monosubstituted by R.sup.8,
[0008] R.sup.5 is linear or branched alkylene having 1-10 carbon
atoms, in which one or two CH.sub.2 groups may be replaced by
--CH.dbd.CH-groups, O, S or SO,
[0009] R.sup.6 is cycloalkyl or cycloalkylalkylene having 5-12
carbon atoms,
[0010] R.sup.7 is phenyl or phenylmethyl,
[0011] R.sup.8 is COOH, COOA, CONH.sub.2, CONHA, CON(A).sub.2 or
CN,
[0012] A is alkyl having from 1 to 6 carbon atoms, and
[0013] Hal is F, Cl, Br or I,
[0014] and/or physiologically acceptable salts and/or solvates
thereof and
[0015] a) at least one antithrombotic or
[0016] b) at least one calcium antagonist or
[0017] c) at least one prostaglandin or prostaglandin
derivative.
[0018] The invention furthermore relates to the use of the
formulation for the preparation of a medicament for the treatment
of angina, high blood pressure, pulmonary hypertension, congestive
heart failure (CHF), chronic obstructive pulmonary disease (COPD),
cor pulmonale, dextrocardiac insufficiency, atherosclerosis,
conditions of reduced patency of heart vessels, peripheral vascular
diseases, strokes, bronchitis, allergic asthma, chronic asthma,
allergic rhinitis, glaucoma, irritable bowel syndrome, tumours,
renal insufficiency, liver cirrhosis and for the treatment of
female sexual disorders.
[0019] Pharmaceutical formulations consisting of other
phosphodiesterase V (PDE V) inhibitors together with a second
active ingredient are described in WO 00/15639.
[0020] Pyrimidine derivatives are disclosed, for example, in EP
201.188 and WO 93/06104.
[0021] The use of other PDE-V inhibitors is described, for example,
in WO 94/28902.
[0022] Pharmaceutical formulations consisting of other
phosphodiesterase V (PDE V) inhibitors together with calcium
antagonists (=calcium channel blockers) are described in WO
00/15639.
[0023] Pharmaceutical formulations consisting of other
phosphodiesterase V (PDE V) inhibitors together with a
prostaglandin or prostaglandin derivative are described in WO
00/15639 and WO 0015228.
[0024] The use of (other) phosphodiesterase IV or V inhibitors in
combination with a prostaglandin or prostaglandin derivative for
the local treatment of erectile dysfunction is described in WO
9921558.
[0025] R. T. Schermuly et al. in the American Journal of
Respiratory and Critical Care Medicine, 160, 1500-6 (1999),
describe the therapeutic potential of prostaglandin I.sub.2
(PGI.sub.2) in aerosol form with systemic PDE inhibitors,
preferably dual-selective PDE III/IV inhibitors, in low doses for
acute and chronic pulmonary hypertension.
[0026] In Pneumologie (54, Suppl. 1, S42, 2000), R. Schermuly et
al. describe the influence of PDE-V inhibition on
prostacyclin-induced vasorelaxation in experimental pulmonary
hypertonia.
[0027] The invention had the object of providing novel medicaments
in the form of pharmaceutical preparations which have better
properties than known medicaments which can be used for the same
purpose.
[0028] This object has been achieved by the discovery of the novel
preparation.
[0029] The compounds of the formula I and their salts have very
valuable pharmacological properties and are well tolerated. In
particular, they exhibit specific inhibition of CGMP
phosphodiesterase (PDE V).
[0030] Quinazolines having a cGMP phosphodiesterase-inhibiting
activity are described, for example, in J. Med. Chem. 36, 3765
(1993) and ibid. 37, 2106 (1994).
[0031] The biological activity of the compounds of the formula I
can be determined by methods as described, for example, in WO
93/06104.
[0032] The affinity of the compounds according to the invention for
cGMP and cAMP phosphodiesterase is determined by measuring their
IC.sub.50 values (concentration of the inhibitor needed to achieve
50% inhibition of the enzyme activity).
[0033] The determinations can be carried out using enzymes isolated
by known methods (for example W. J. Thompson et al., Biochem. 1971,
10, 311). The experiment can be carried out using a modified batch
method of W. J. Thompson and M. M. Appleman (Biochem. 1979, 18,
5228).
[0034] The compounds are therefore suitable for the treatment of
illnesses of the cardiovascular system, in particular cardiac
insufficiency, and for the treatment and/or therapy of impotence
(erectile dysfunction).
[0035] The use of substituted pyrazolopyrimidinones for the
treatment of impotence is described, for example, in WO
94/28902.
[0036] The compounds are effective as inhibitors of
phenylephrine-induced contractions in corpus cavernosum
preparations of rabbits. This biological action can be
demonstrated, for example, by the method described by F. Holmquist
et al. in J. Urol., 150,1310-1315 (1993).
[0037] The inhibition of the contraction demonstrates the
effectiveness of the compounds according to the invention for the
therapy and/or treatment of impotence.
[0038] The efficacy of the pharmaceutical formulations according to
the invention, in particular for the treatment of pulmonary
hypertension, can be demonstrated, as described by E. Braunwald in
Heart Disease 5.sup.th edition, W B Saunders Company, 1997, Chapter
6: Cardiac Catheterisation, 177-200.
[0039] The compounds of the formula I can be employed as medicament
active ingredients in human and veterinary medicine. They can
furthermore be employed as intermediates for the preparation of
further medicament active ingredients.
[0040] The compounds of the formula I according to claim 1 and
their salts are prepared by a process which is characterised in
that
[0041] a) a compound of the formula II 3
[0042] in which
[0043] R.sup.3, R.sup.4 and X are as defined above,
[0044] and L is Cl, Br, OH, SCH.sub.3 or a reactive esterified OH
group,
[0045] is reacted with a compound of the formula III 4
[0046] in which
[0047] R.sup.1 and R.sup.2 are as defined above, or
[0048] b) a radical X in a compound of the formula I is converted
into another radical X by, for example, hydrolysing an ester group
to a COOH group or converting a COOH group into an amide or into a
cyano group,
[0049] and/or in that a compound of the formula I is converted into
one of its salts.
[0050] The invention also relates to the use of all optically
active forms (stereoisomers), the enantiomers, the racemates, the
diastereomers, and the hydrates and solvates of the compounds.
[0051] The term solvates of the compounds of the formula I is taken
to mean adductions of inert solvent molecules onto the compounds of
the formula I which form owing to their mutual attractive force.
Solvates are, for example, monohydrates or dihydrates or
alkoxides.
[0052] Above and below, the radicals R.sup.1, R.sup.2, R.sup.3,
R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, X and L are as defined
under the formulae I, II and III, unless expressly stated
otherwise.
[0053] A is alkyl having 1-6 carbon atoms.
[0054] In the above formulae, alkyl is preferably unbranched and
has 1, 2, 3, 4, 5 or 6 carbon atoms and is preferably methyl, ethyl
or propyl, furthermore preferably isopropyl, butyl, isobutyl,
sec-butyl or tert-butyl, but also n-pentyl, neopentyl, isopentyl or
hexyl.
[0055] X is an R.sup.5, R.sup.6 or R.sup.7 radical which is
monosubstituted by R.sup.8.
[0056] R.sup.5 is a linear or branched alkylene radical having 1-10
carbon atoms, where the alkylene radical is preferably, for
example, methylene, ethylene, propylene, isopropylene, butylene,
isobutylene, sec-butylene, pentylene, 1- , 2- or 3-methyl butylene,
1,1- , 1,2- or 2,2-dimethylpropylene, 1-ethyl-propylene, hexylene,
1- , 2- , 3- or 4-methylpentylene, 1,1- , 1,2-, 1,3-, 2,2- , 2,3-
or 3,3-dimethylbutylene, 1-or 2-ethylbutylene,
1-ethyl-1-methylpropylene, 1-ethyl-2-methylpropylene, 1,1,2- or
1,2,2-trimethylpropylene, linear or branched heptylene, octylene,
nonylene or decylene.
[0057] R.sup.5 is furthermore, for example, but-2-enylene or
hex-3-enylene.
[0058] A CH.sub.2 group in R.sup.5 may preferably be replaced by
oxygen.
[0059] Very particular preferance is given to ethylene, propylene,
butylene or CH.sub.2--O--CH.sub.2.
[0060] R.sup.6 is cycloalkylalkylene having 5-12 carbon atoms,
preferably, for example, cyclopentylmethylene, cyclohexylmethylene,
cyclohexylethylene, cyclohexylpropylene or cyclohexylbutylene.
[0061] R.sup.6 is alternatively cycloalkyl, preferably having 5-7
carbon atoms.
[0062] Cycloalkyl is, for example, cyclopentyl, cyclohexyl or
cycloheptyl.
[0063] Hal is preferably F, Cl or Br, but also I.
[0064] The radicals R.sup.1 and R.sup.2 may be identical or
different and are preferably located in the 3- or 4-position of the
phenyl ring. They are, for example, in each case independently of
one another, H, alkyl, OH, F, Cl, Br or I or together are alkylene,
such as, for example, propylene, butylene or pentylene, furthermore
ethyleneoxy, methylenedioxy or ethylenedioxy. They are preferably
also in each case alkoxy, such as, for example, methoxy, ethoxy or
propoxy.
[0065] The radical R.sup.8 is preferably, for example, COOH, COOA,
such as, for example, COOCH.sub.3 or COOC.sub.2H.sub.5, CONH.sub.2,
CON(CH.sub.3).sub.2, CONHCH.sub.3 or CN, but in particular COOH or
COOA.
[0066] For the entire invention, all radicals which occur more than
once may be identical or different, i.e. are independent of one
another.
[0067] The term antithrombotics also covers so-called
anticoagulants and blood platelet aggregation inhibitors
(thrombocyte aggregation inhibitors).
[0068] The invention relates in particular to pharmaceutical
formulations comprising an antithrombotic, a calcium antagonist or
a prostaglandin or prostaglandin derivative and at least one
compound of the formula I in which at least one of the said
radicals has one of the preferred meanings indicated above. Some
preferred groups of compounds may be expressed by the following
sub-formulae Ia to If, which conform to the formula I and in which
the radicals not designated in greater detail are as defined under
the formula I, but in which
[0069] in Ia X is R.sup.5, phenyl or phenylmethyl, each of which is
substituted by COOH, COOA, CONH.sub.2, CONA.sub.2, CONHA or CN;
[0070] in Ib R.sup.1 and R.sup.2 together are alkylene having 3-5
carbon atoms, --O--CH.sub.2--CH.sub.2--, --O--CH.sub.2--O-- or
--O--CH.sub.2--CH.sub.2--O--,
[0071] X is R.sup.5, phenyl or phenylmethyl, each of which is
substituted by COOH, COOA, CONH.sub.2, CONA.sub.2, CONHA or CN;
[0072] in Ic R.sup.1 and R.sup.2 are each, independently of one
another, H, A, OH, OA or Hal,
[0073] R.sup.1 and R.sup.2 together are alternatively alkylene
having 3-5 carbon atoms, --O--CH.sub.2--CH.sub.2--,
--O--CH.sub.2--O-- or --O--CH.sub.2--CH.sub.2--O--,
[0074] X is R.sup.5, phenyl or phenylmethyl, each of which is
substituted by COOH, COOA, CONH.sub.2, CONA.sub.2, CONHA or CN;
[0075] in Id R.sup.1 and R.sup.2 are each, independently of one
another, H, A, OH, OA or Hal,
[0076] R.sup.1 and R.sup.2 together are alternatively alkylene
having 3-5 carbon atoms, --O--CH.sub.2--CH.sub.2--,
--O--CH.sub.2--O-- or --O--CH.sub.2--CH.sub.2--O--,
[0077] X is alkylene having 2-5 carbon atoms, cyclohexyl, phenyl or
phenylmethyl, each of which is mono-substituted by R.sup.8,
[0078] R.sup.3 is alkyl having 1-6 carbon atoms,
[0079] R.sup.4 is alkyl having 1-6 carbon atoms,
[0080] R.sup.8 is COOH or COOA,
[0081] A is alkyl having from 1 to 6 carbon atoms,
[0082] Hal is F, Cl, Br or I;
[0083] in Ie R.sup.1 and R.sup.2 are each, independently of one
another, H, A, OH, OA or Hal,
[0084] R.sup.1 and R.sup.2 together are alternatively alkylene
having 3-5 carbon atoms, --O--CH.sub.2--CH.sub.2--,
--O--CH.sub.2--O-- or --O--CH.sub.2--CH.sub.2--O--,
[0085] R.sup.3 is alkyl having 1-6 carbon atoms,
[0086] R.sup.4 is alkyl having 1-6 carbon atoms,
[0087] X is --(CH.sub.2).sub.2-5--R.sup.8, 4-R.sup.8-cyclohexyl,
4-R.sup.8-phenyl or 4-(R.sup.8-methyl)phenyl;
[0088] in If R.sup.1 and R.sup.2 are each, independently of one
another, H, A, OH, OA or Hal,
[0089] R.sup.1 and R.sup.2 together are alternatively alkylene
having 3-5 carbon atoms, --O--CH.sub.2--CH.sub.2--,
--O--CH.sub.2--O-- or --O--CH.sub.2--CH.sub.2O--,
[0090] R.sup.3 is alkyl having 1-6 carbon atoms,
[0091] R.sup.4 is alkyl having 1-6 carbon atoms,
[0092] X is --(CH.sub.2).sub.2-5--R.sup.8, in which one CH.sub.2
group may be replaced by 0, or is 4-R.sup.8-cyclohexyl,
4-R.sup.8-phenyl or 4-(R.sup.8-methyl)phenyl,
[0093] R.sup.8 is COOH or COOA.
[0094] The invention preferably relates to a formulation comprising
[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]py-
rimidin-5-yl-methoxy]acetic acid and physiologically acceptable
salts and/or solvates thereof and an antithrombotic.
[0095] Besides the free acid, the ethanolamine salt is
preferred.
[0096] Preferred antithrombotics are vitamin K antagonists, heparin
compounds, thrombocyte aggregation inhibitors, enzymes, factor Xa
inhibitors, factor Vila inhibitors and other antithrombotic
agents.
[0097] Preferred vitamin K antagonists are selected from the group
consisting of dicoumarol, phenindione, warfarin, phenprocoumon,
acenocoumarol, ethyl biscoumacetate, clorindione, diphenadione and
tioclomarol.
[0098] Preferred heparin compounds are selected from the group
consisting of heparin, antithrombin III, dalteparin, enoxaparin,
nadroparin, parnaparin, reviparin, danaparoid, tinzaparin and
sulodexide.
[0099] Preferred thrombocyte aggregation inhibitors are selected
from the group consisting of ditazole, cloricromen, picotamide,
clopidogrel, ticlopidine, acetylsalicylic acid, dipyridamole,
calcium carbassalate, epoprostenol, indobufen, iloprost, abciximab,
tirofiban, aloxiprin and intrifiban.
[0100] Preferred enzymes are selected from the group consisting of
streptokinase, alteplase, anistreplase, urokinase, fibrinolysin,
brinase, reteplase and saruplase.
[0101] Preferred antithrombotics are furthermore the blood platelet
glycoprotein receptor (IIIb/IIIa) antagonists which inhibit blood
platelet aggregation. Preferred compounds are described, for
example, in EP 0 623 615 B1 on page 2 or in EP 0 741 133 A2, page
2, line 2, to page 4, line 56.
[0102] Preferred factor Xa and VIIa inhibitors are, for
example,
[0103] a) the compounds of the formula I 5
[0104] in which
[0105] R.sup.1 is --C(.dbd.NH)--NH.sub.2, which may also be
monosubstituted by --COA, --CO-[C(R.sup.6).sub.2].sub.n--Ar,
--COOA, --OH or by a conventional amino protecting group, or is
6
[0106] R.sup.2 is H, A, OR.sup.6, N(R.sup.6).sub.2, NO.sub.2, CN,
Hal, NHCOA, NHCOAr, NHSO.sub.2A, NHSO.sub.2Ar, COOR.sup.6,
CON(R.sup.6).sub.2, CONHAr, COR.sup.6, COAr, S(O).sub.nA or
S(O).sub.nAr,
[0107] R.sup.3 is A, cycloalkyl, --[C(R.sup.6]Ar,
--[C(R.sup.6).sub.2].sub- .n--O--Ar, [C(R.sup.6).sub.2].sub.nHet or
--C(R.sup.6).sub.2.dbd.C(R.sup.6- ).sub.2--Ar,
[0108] R.sup.6 is H, A or benzyl,
[0109] X is absent or is --CO--, --C(R.sup.6).sub.2--,
--C(R.sup.6).sub.2--C(R.sup.6).sub.2--, --C(R.sup.6).sub.2--CO--,
--C(R.sup.6).sub.2--C(R.sup.6).sub.2--CO--,
--C(R.sup.6).dbd.C(R.sup.6)--- CO--, NR.sup.6CO--,
--N{[C(R.sup.6).sub.2].sub.n--COOR.sup.5}--CO-- or
--C(COOR.sup.6)R.sup.6--C(R.sup.6).sub.2--CO--,
[0110] Y is --C(R.sup.6).sub.2--, --SO.sub.2--, --CO--, --COO-- or
--CONR.sup.6--,
[0111] A is alkyl having 1-20 carbon atoms, in which one or two
CH.sub.2 groups may be replaced by O or S atoms or by
--CR.sup.6.dbd.CR.sup.6-- groups and/or 1-7H atoms may be replaced
by F,
[0112] Ar is phenyl or naphthyl, each of which is unsubstituted or
monosubstituted, disubstituted or trisubstituted by A, Ar',
OR.sup.6, N(R.sup.6).sub.2, NO.sub.2, CN, Hal, NHCOA, NHCOAr',
NHSO.sub.2A, NHSO.sub.2Ar', COOR.sup.6, CON(R.sup.6).sub.2,
CONHAr', COR.sup.6, COAr', S(O)NA or S(O).sub.nAr,
[0113] Ar' is phenyl or naphthyl, each of which is unsubstituted or
monosubstituted, disubstituted or trisubstituted by A, OR.sup.6,
N(R.sup.6).sub.2, NO.sub.2, CN, Hal, NHCOA, COOR.sup.6,
CON(R.sup.6).sub.2, COR.sup.6 or S(O).sub.nA,
[0114] Het is a monocyclic or bicyclic, saturated or unsaturated
heterocyclic ring system which contains one, two, three or four
identical or different heteroatoms, such as nitrogen, oxygen and
sulfur, and is unsubstituted or monosubstituted or polysubstituted
by Hal, A, Ar', COOR.sup.6, CN, N(R.sup.2, NO.sub.2,
Ar--CONH--CH.sub.2 and/or carbonyl oxygen,
[0115] Hal is F, Cl, Br or I,
[0116] n is 0, 1 or 2,
[0117] and salts thereof,
[0118] which are described in WO 9916751,
[0119] b) the compounds of the formula I 7
[0120] in which
[0121] R.sup.1 is --C(.dbd.NH)--NH.sub.2, which may also be
monosubstituted by --COA, --CO--[C(R.sup.5).sub.2].sub.m--Ar,
--COOA, --OH or by a conventional amino-protecting group, or is
8
[0122] R.sup.2 is H, A, OR.sup.5, N(R.sup.5).sub.2, NO.sub.2, CN,
Hal, NR.sup.5COA, NHCOAr, NHSO.sub.2A, NHSO.sub.2Ar, COOR.sup.5,
CON(R.sup.5).sub.2, CONHAr, COR.sup.5, COAr, S(O).sub.nRA or
S(O).sub.nAr,
[0123] R.sup.3 is R.sup.5 or --[C(R.sup.5).sub.2] COOR.sup.5,
[0124] R.sup.3 and X together are alternatively --CO--N--, with
formation of a 5-membered ring,
[0125] where R.sup.3 is --C.dbd.O and X is N,
[0126] R.sup.4 is A, cycloalkyl, --[C(R.sup.5).sub.2].sub.mAr,
--[C(R.sup.5).sub.2].sub.mHet or --CR.sup.5.dbd.CR.sup.5--Ar,
[0127] R.sup.5 is H, A or benzyl,
[0128] X is O, NR.sup.5 or CH.sub.2,
[0129] Y is O, NR.sup.5, N[C(R.sup.5).sub.2].sub.m--Ar,
N[C(R.sup.5).sub.2].sub.m-Het, 9
[0130] N[C(R.sup.5).sub.2].sub.m--CON(R.sup.5).sub.2,
N[C(R.sup.5).sub.z].sub.m--CONR.sup.5Ar or
N[C(R.sup.5).sub.2].sub.m--CON- Ar.sub.2,
[0131] W is a bond, --SO.sub.2--, --CO--, --COO-- or
--CONR.sup.5--,
[0132] A is alkyl having 1-20 carbon atoms, in which one or two
CH.sub.2 groups may be replaced by O or S atoms or by
--CR.sup.5.dbd.CR.sup.5-- groups and/or 1-7H atoms may be replaced
by F,
[0133] Ar is phenyl or naphthyl, each of which is unsubstituted or
monosubstituted, disubstituted or trisubstituted by R.sup.1, A,
Ar', OR.sup.5, N(R.sup.5).sub.2, NO.sub.2, CN, Hal, NHCOA, NHCOAr',
NHSO.sub.2A, NHSO.sub.2Ar', COOR.sup.5, CON(R.sup.5).sub.2,
CONHAr', COR.sup.5, COAr', S(O).sub.nA or S(O).sub.nAr,
[0134] Ar' is phenyl or naphthyl, each of which is unsubstituted or
monosubstituted, disubstituted or trisubstituted by R.sup.1, A,
OR.sup.5, N(R.sup.5).sub.2, NO.sub.2, CN, Hal, NHCOA, COOR.sup.5,
CON(R.sup.5).sub.2, COR.sup.5 or S(O).sub.nA,
[0135] Het is a monocyclic or bicyclic, saturated or unsaturated
heterocyclic ring system which contains one, two, three or four
identical or different heteroatoms, such as nitrogen, oxygen and
sulfur, and which is unsubstituted or monosubstituted or
polysubstituted by Hal, A, Ar', OR.sup.5, COOR.sup.5, CN,
N(R.sup.5).sub.2, NO.sub.2, NHCOA, NHCOAr' and/or carbonyl
oxygen,
[0136] Hal is F, Cl, Br or I,
[0137] m is 0, 1, 2, 3 or 4,
[0138] n is 0, 1 or 2,
[0139] and salts thereof,
[0140] which are described in WO 9931092,
[0141] c) the compounds of the formula I 10
[0142] in which
[0143] R.sup.1 and R.sup.4 are each, independently of one another,
--C(.dbd.NH)--NH.sub.2, which may also be monosubstituted by --COA,
--CO-[C(R.sup.6).sub.2].sub.n--Ar, --COOA, --OH or by a
conventional amino-protecting group,
[0144] or are NH--C(.dbd.NH)--NH.sub.2,
--CO--N.dbd.C(NH.sub.2).sub.2, 11
[0145] R.sup.2, R.sup.3
[0146] and R.sup.5 are each, independently of one another, H, A,
OR.sup.6, N(R.sup.6).sub.2, NO.sub.2, CN, Hal, NHCOA, NHCOAr,
NHSO.sub.2A, NHSO.sub.2Ar, COOR.sup.6, CON(R.sup.6), CONHAr,
COR.sup.6, COAr, S(O).sub.nA, S(O)Ar,
--O-[C(R.sup.6).sub.2].sub.m--COOR.sup.6,
--[C(R.sup.6).sub.2].sub.p--COOR.sup.6,
--O--[C(R.sup.6)].sub.m--CON(R.su- p.6).sub.2,
--[C(R.sup.6).sub.2].sub.p--CON(R.sup.6).sub.2,
--O--[C(R.sup.6).sub.2].sub.m--CONHAr or
--[C(R.sup.6).sub.2].sub.p--CONH- Ar,
[0147] X is --[C(R.sup.6).sub.2].sub.n--,
--CR.sup.6.dbd.CR.sup.6--, --[C(R.sup.6).sub.2].sub.n--O--,
--O--[C(R.sup.6).sub.2].sub.n--, --COO--, --OOC--, --CONR.sup.6--
or --NR.sup.6CO--,
[0148] R.sup.6 is H, A or benzyl,
[0149] A is alkyl having 1-20 carbon atoms, in which one or two
CH.sub.2 groups may be replaced by O or S atoms or by
--CR.sup.6.dbd.CR.sup.6-- groups and/or 1-7H atoms may be replaced
by F,
[0150] Ar is phenyl or naphthyl, each of which is unsubstituted or
monosubstituted, disubstituted or trisubstituted by A, Ar',
OR.sup.6, OAr', N(R.sup.6).sub.2, NO.sub.2, CN, Hal, NHCOA,
NHCOAr', NHSO.sub.2A, NHSO.sub.2Ar', COOR.sup.6,
CON(R.sup.6).sub.2, CONHAr', COR.sup.6, COAr', S(O).sub.nA or
S(O).sub.nAr',
[0151] Ar' is phenyl or naphthyl, each of which is unsubstituted or
monosubstituted, disubstituted or trisubstituted by A, OR.sup.6,
N(R.sup.6).sub.2, NO.sub.2, CN, Hal, NHCOA, COOR.sup.6,
CON(R.sup.6).sub.2, COR.sup.6 or S(O).sub.nA,
[0152] Hal is F, Cl, Br or I,
[0153] n is 0, 1 or 2,
[0154] m is 1 or 2,
[0155] p is 1 or 2,
[0156] and salts thereof,
[0157] which are described in WO 9957096,
[0158] d) the compounds of the formula I 12
[0159] in which
[0160] R and R.sup.1 are each, independently of one another, H, A,
--(CH.sub.2).sub.m--R.sup.4, --(CH.sub.2).sub.m--OA or
--(CH.sub.2).sub.m--Ar,
[0161] R.sup.2 13
[0162] R.sup.3 is Ar,
[0163] R.sup.4 is CN, COOH, COOA, CONH.sub.2, CONHA, CONA.sub.2 or
C(.dbd.NH)--NH.sub.2,
[0164] R.sup.5 is --C(.dbd.NH)--NH.sub.2,
--NH--C(.dbd.NH)--NH.sub.2 or --C(.dbd.O)--N.dbd.C(NH.sub.2).sub.2,
each of which is unsubstituted or monosubstituted by --COA, --COOA,
--OH or by a conventional amino-protecting group, or is 14
[0165] R.sup.6 is H, A or NH.sub.2,
[0166] Ar is phenyl, naphthyl or biphenyl, each of which is
unsubstituted or monosubstituted, disubstituted or trisubstituted
by A, cycloalkyl having 3-6 carbon atoms, OH, OA, Hal, CN,
NO.sub.2, CF.sub.3, NH.sub.2, NHA, NA.sub.2, pyrrolidin-1-yl,
piperidin-1-yl, benzyloxy, SO.sub.2NH.sub.2, SO.sub.2NHA,
SO.sub.2NA.sub.2, --(CH.sub.2).sub.n--NH.s- ub.2,
--(CH.sub.2).sub.n--NHA, --(CH.sub.2).sub.n--NA.sub.2,
--O--(CH.sub.2).sub.n--NH.sub.2, --O--(CH.sub.2).sub.n--NHA,
--O--(CH.sub.2).sub.n--NA.sub.2, --O--(CH.sub.2).sub.m--O-- or
R.sup.5,
[0167] A is alkyl having. 1-6 carbon atoms,
[0168] X is absent or is alkylene having 14 carbon atoms or
carbonyl,
[0169] Y is absent or is NH, O or S,
[0170] Hal is F, Cl, Br or I,
[0171] m is 0, 1 or 2,
[0172] n is 0, 1, 2 or 3,
[0173] and salts thereof,
[0174] which are described in WO 0012479,
[0175] e) the compounds of the formula I 15
[0176] in which
[0177] R is H, unbranched or branched alkyl having 1-6 carbon atoms
or cycloalkyl having 3-6 carbon atoms,
[0178] R.sup.1 is Ar,
[0179] R.sup.2 is Ar',
[0180] R.sup.3 is H, R, R.sup.4, Hal, CN, COOH, COOA or
CONH.sub.2,
[0181] Ar and Ar' are each, independently of one another, phenyl,
naphthyl or biphenyl, each of which is unsubstituted or
monosubstituted, disubstituted or trisubstituted by R, OH, Hal, CN,
NO.sub.2, CF.sub.3, NH.sub.2, NHR, NR.sub.2, pyrrolidin-1-yl,
piperidin-1-yl, benzyloxy, SO.sub.2NH.sub.2, SO.sub.2NHR,
SO.sub.2NR.sub.2, --CONHR, --CONR.sub.2,
--(CH.sub.2).sub.n--NH.sub.2, --(CH.sub.2).sub.n--NHR,
--(CH.sub.2).sub.n--NR.sub.2, --O--(CH.sub.2).sub.n--NH.sub.2,
--O--(CH.sub.2).sub.n--NHR, --O--(CH.sub.2).sub.n--NR.sub.2,
R.sup.4 or together by --O--(CH.sub.2).sub.m--O--,
[0182] R.sup.4 is --C(.dbd.NH)--NH.sub.2,
--NH--C(.dbd.NH)--NH.sub.2 or --C(.dbd.O)--N.dbd.C(NH.sub.2).sub.2,
each of which is unsubstituted or monosubstituted by --COR, --COOR,
--OH or by a conventional amino-protecting group, or is 16
[0183] A is alkyl having 1-4 carbon atoms,
[0184] Hal is F, Cl, Br or I,
[0185] m is 1 or 2,
[0186] n is 0, 1, 2 or 3,
[0187] p is 0 or 1,
[0188] and salts thereof,
[0189] which are described in WO 0020416,
[0190] f) the compounds of the formula I 17
[0191] in which
[0192] R is H, unbranched or branched alkyl having 1-6 carbon atoms
or cycloalkyl having 3-6 carbon atoms,
[0193] R.sup.1 is Ar,
[0194] R.sup.2 is Ar',
[0195] R.sup.3 is H, R, R.sup.4, Hal, CN, COOH, COOA or
CONH.sub.2,
[0196] Ar and Ar' are each, independently of one another, phenyl,
naphthyl or biphenyl, each of which is unsubstituted or
monosubstituted, disubstituted or trisubstituted by R, OH, Hal, CN,
NO.sub.2, CF.sub.3, NH.sub.2, NHR, NR.sub.2, pyrrolidin-1-yl,
piperidin-1-yl, benzyloxy, SO.sub.2NH.sub.2, SO.sub.2NHR,
SO.sub.2NR.sub.2, --CONHR, --CONR.sub.2,
--(CH.sub.2).sub.n--NH.sub.2, --(CH.sub.2).sub.n--NHR,
--(CH.sub.2).sub.n--NR.sub.2, --O--(CH.sub.2).sub.n--NH.sub.2,
--O--(CH.sub.2).sub.n--NHR, --O--(CH.sub.2).sub.n--NR.sub.2,
R.sup.4 or together by --O--(CH.sub.2).sub.m--O--, or isoquinolinyl
which is substituted by NH.sub.2,
[0197] R.sup.4 is --C(.dbd.NH)--NH.sub.2,
--NH--C(.dbd.NH)--NH.sub.2 or --C(.dbd.O)--N.dbd.C(NH.sub.2).sub.2,
each of which is unsubstituted or monosubstituted by --COR, --COOR,
--OH or by a conventional amino-protecting group, or is 18
[0198] A is alkyl having 14 carbon atoms,
[0199] Hal is F, Cl, Br or I,
[0200] m is 1 or 2,
[0201] n is 0 or 1,
[0202] and salts and solvates thereof,
[0203] which are described in WO 0040583,
[0204] g) the compounds of the formula I 19
[0205] in which
[0206] R.sup.1 and R.sup.2 are each, independently of one another,
H, A, cycloalkyl-[C(R.sup.7R.sup.740)].sub.n-- or
Ar--[C(R.sup.7R.sup.7')].sub.- n--,
[0207] R.sup.3 and R.sup.4 are each, independently of one another,
H, Ar, Het or R.sup.5, where at least one of the two radicals is
R.sup.5,
[0208] R.sup.5 is phenyl, naphthyl or biphenyl, each of which is
substituted by --C(.dbd.NH.sub.1--NH.sub.2, which may also be
monosubstituted by --COA, Ar-[C(R.sup.7R.sup.7)].sub.n--CO--, COOA,
OH or by a conventional amino-protecting group,
--NH--C(.dbd.NH)--NH.sub.2, --CO--N.dbd.C(NH.sub.2).sub.2, 20
[0209] and which may optionally additionally be monosubstituted or
disubstituted by A, Ar', Het, OR.sup.6, NR.sup.6R.sup.6', NO.sub.2,
CN, Hal, NR.sup.6COA, NR.sup.6COAr', NR.sup.6SO.sub.2A,
NR.sup.6SO.sub.2Ar', COOR.sup.6, CO--NR.sup.6R.sup.6, COR.sup.7,
CO--Ar', SO.sub.2NR.sup.6R.sup.6', S(O).sub.nAr' or
S(O).sub.nA,
[0210] R.sup.6 and R.sup.6' are each, independently of one another,
H, A, CR.sup.7R.sup.7'--Ar or CR.sup.7R.sup.7'-Het,
[0211] R.sup.7 and R.sup.7' are each, independently of one another,
H or A,
[0212] X and Y are each, independently of one another,
(CR.sup.7R.sup.7').sub.n,
[0213] A is alkyl having 1-20 carbon atoms, in which one or two
CH.sub.2 groups may be replaced by O or S atoms and/or by
--CH.dbd.CH-- groups and/or in addition 1-7H atoms may be replaced
by F,
[0214] Ar is phenyl, naphthyl or biphenyl, each of which is
unsubstituted or monosubstituted, disubstituted or trisubstituted
by A, Ar, Het, OR.sup.6.sub.9 NR.sup.6R.sup.6', NO.sub.2, CN, Hal,
NR.sup.6COA, NR.sup.6COAr', NR.sup.6SO.sub.2A, NR.sup.6SO.sub.2Ar',
COOR.sup.6, CO--NR.sup.6R.sup.6', CON.sup.6Ar', COR.sup.7, COAr',
SO.sub.2NR.sup.6R.sup.6', S(O)Ar' or S(O).sub.nA,
[0215] Ar' is phenyl or naphthyl, each of which is unsubstituted or
monosubstituted, disubstituted or trisubstituted by A, OR.sup.7,
NR.sup.7R.sup.7', NO.sub.2, CN, Hal, NR.sup.7COA,
NR.sup.7SO.sub.2A, COOR.sup.7, CO--NR.sup.7R.sup.7', COR.sup.7,
SO.sub.2NR.sup.7R.sup.7' or S(O).sub.nA,
[0216] Het is a monocyclic or bicyclic, saturated, unsaturated or
aromatic heterocyclic radical having from 1 to 4 N, O and/or S
atoms, which may be unsubstituted or monosubstituted, disubstituted
or trisubstituted by A, OR.sup.7, NR.sup.7R.sup.7', NO.sub.2, CN,
Hal, NR.sup.7COA, NR.sup.7SO.sub.2A, COOR.sup.7,
CO--NR.sup.7R.sup.7', COR.sup.7, SO.sub.2NR.sup.7R.sup.7',
S(O).sub.nA and/or carbonyl oxygen,
[0217] Hal is F, Cl, Br or I,
[0218] n is 0, 1 or 2,
[0219] and their pharmaceutically tolerated salts and solvates,
[0220] which are described in WO 0051989,
[0221] h) compounds of the formula I 21
[0222] in which
[0223] R is --CO--N.dbd.C(NH.sub.2).sub.2,
--NH--C(.dbd.NH)--NH.sub.2 or --C(.dbd.NH)--NH.sub.2, which may
also be monosubstituted by OH, --OCOOA, --OCOO(CH.sub.2).sub.nNAA',
--COO(CH.sub.2).sub.nNAA', --OCOO(CH.sub.2).sub.m-Het,
--COO(CH.sub.2).sub.m-Het, --CO--CAA'--R.sup.3,
--COO--CAA'--R.sup.3, COOA, COSA, COOAr, COOAr or by a conventional
amino-protecting group, or is 22
[0224] R.sup.1 is unbranched, branched or cyclic alkyl having 1-20
carbon atoms, in which one or two CH.sub.2 groups may be replaced
by O or S atoms, or is Ar, Ar or X,
[0225] R.sup.2 is phenyl which is monosubstituted by S(O).sub.pA,
S(O).sub.pNHA, CF.sub.3, COOA, CH.sub.2NHA, CN or OA,
[0226] R.sup.3 23
[0227] Ar is phenyl or naphthyl, each of which is unsubstituted or
monosubstituted, disubstituted or trisubstituted by A, OA, NAA',
NO.sub.2, CF.sub.3, CN, Hal, NHCOA, COOA, CONAA', S(O).sub.pA or
S(O).sub.pNAA',
[0228] Ar is --(CH.sub.2).sub.n--Ar,
[0229] A and A' are each, independently of one another, H or
unbranched, branched or cyclic alkyl having 1-20 carbon atoms,
[0230] Het is a monocyclic or bicyclic, saturated, unsaturated or
aromatic heterocyclic radical having from 1 to 4 N, O and/or S
atoms, bonded via N or C, which may be unsubstituted or substituted
by A,
[0231] X is --(CH.sub.2).sub.n--Y,
[0232] Y 24
[0233] Hal is F, Cl, Br or I,
[0234] m is 0 or 1,
[0235] n is 1, 2, 3, 4, 5 or 6,
[0236] p is 0, 1 or 2,
[0237] and their pharmaceutically tolerated salts and solvates,
[0238] i) compounds of the formula I 25
[0239] in which
[0240] R is --CO--N.dbd.C(NH.sub.2).sub.2,
--NH--C(.dbd.NH)--NH.sub.2 or --C(.dbd.NH)--NH.sub.2, which may
also be monosubstituted by OH, --OCOOA, --OCOO(CH.sub.2).sub.nNAA',
--COO(CH.sub.2).sub.nNAA', --OCOO(CH.sub.2).sub.m-Het,
--COO(CH.sub.2).sub.m-Het, --CO--CAA'--R.sup.3,
--COO--CAA'--R.sup.3, COOA, COSA, COOAr, COOAr' or by a
conventional amino-protecting group, or is 26
[0241] R.sup.1 is unbranched, branched or cyclic alkyl having 1-20
carbon atoms, in which one or two CH.sub.2 groups may be replaced
by O or S atoms, or is Ar, Ar' or X,
[0242] R.sup.2 is phenyl which is monosubstituted by S(O).sub.pA,
S(O).sub.pNHA, CF.sub.3, COOA, CH.sub.2NHA, CN or OA,
[0243] R.sup.3 is --C(Hal).sub.3, --O(C.dbd.O)A or 27
[0244] Ar is phenyl or naphthyl, each of which is unsubstituted or
monosubstituted, disubstituted or trisubstituted by A, OA, NAA',
NO.sub.2, CF.sub.3, CN, Hal, NHCOA, COOA, CONAA', S(O).sub.pA or
S(O).sub.pNAA',
[0245] Ar' is --(CH.sub.2).sub.n--Ar,
[0246] A and A' are each, independently of one another, H or
unbranched, branched or cyclic alkyl having 1-20 carbon atoms,
[0247] Het is a monocyclic or bicyclic, saturated, unsaturated or
aromatic heterocyclic radical having from 1 to 4 N, O and/or S
atoms, bonded via N or C, which may be unsubstituted or substituted
by A,
[0248] X is --(CH.sub.2).sub.n--Y,
[0249] Y 28
[0250] Hal is F, Cl, Br or I,
[0251] m is 0 or 1,
[0252] n is 1, 2, 3, 4, 5 or 6,
[0253] p is 0, 1 or 2,
[0254] and their pharmaceutically tolerated salts and solvates,
[0255] j) compounds of the formula I 29
[0256] in which
[0257] R.sup.1 is H, Cl, F, OH, OA, O--(CH.sub.2).sub.n--Ar,
NH.sub.2, NHCOA, NHCOOA, NH--(CH.sub.2).sub.n--Ar, CN, CONH.sub.2,
CSNH.sub.2, C(.dbd.NH)SA, C(.dbd.NH)NH.sub.2,
C(.dbd.NH--OH)--NH.sub.2, C(.dbd.NH--O--COA)-NH.sub.2,
C(.dbd.NH--O--COAr)NH.sub.2, C(.dbd.NH--O--COHet)-NH.sub.2,
C(.dbd.NH)--OA, C(.dbd.NH)NHNH.sub.2, C(.dbd.NH)NHNHA,
C(.dbd.NH)NH--COOA, C(.dbd.NH)NH--COA,
C(.dbd.NH)NH--COO--(CH.sub.2).sub.m--Ar,
C(.dbd.NH)NH--COO--(CH.sub.2).su- b.m--Het, NH--C(.dbd.NH)NH.sub.2,
NH--C(.dbd.NH )NH--COOA, NHC(.dbd.NH)NH--COO--(CH.sub.2).sub.m--Ar,
30
[0258] R.sup.2 R.sup.2'
[0259] and R.sup.2 are each, independently of one another, H, A,
CF.sub.3, Cl, F, COA, COOH, COOA, CONH.sub.2, CONHA, CONA.sub.2,
CH.sub.2NH.sub.2, CH.sub.2NHCOA, CH.sub.2NHCOOA, OH, OA, OCF.sub.3,
NO.sub.2, SO.sub.2A, SO.sub.2NH.sub.2 or SO.sub.2NHA,
[0260] R.sup.3 and R.sup.4 together are (CH.sub.2).sub.p,
CO(CH.sub.2).sub.p, COO(CH.sub.2).sub.n, COOCH(A)-, COOCH(Ar)--,
CONH(CH.sub.2).sub.n, CH.sub.2CH(OR.sup.7)--(CH.sub.2).sub.n--,
CH.sub.2--O--(CH.sub.2).sub.n, CH.sub.2--S--(CH.sub.2).sub.n,
CA.sub.2--O--(CH.sub.2).sub.n, CA.sub.2--S--(CH.sub.2).sub.n,
CHAr--S--(CH.sub.2).sub.n, (CH.sub.2).sub.2NHCH.sub.2 or
(CH.sub.2).sub.2--N(R.sup.8)--CH.sub.2,
[0261] R.sup.5, R.sup.5', R.sup.5",
[0262] R.sup.5'" and R.sup.5"" are each, independently of one
another, (CH.sub.2).sub.n--COOH,
(CH.sub.2).sub.n--COO--(CH.sub.2).sub.n--Ar, Ar, Py or R.sup.2,
[0263] R.sup.6 is OH, A or Ar,
[0264] R.sup.7 is H, A, Ar or Het,
[0265] R.sup.8 is H, (CH.sub.2).sub.n--COOH,
(CH.sub.2).sub.m--COOA,
(CH.sub.2).sub.m--COO--(CH.sub.2).sub.n--Ar,
(CH.sub.2).sub.m--COO--(CH.s- ub.2).sub.n-Het,
(CH.sub.2).sub.m--CONH.sub.2, (CH.sub.2).sub.m--CONHA,
(CH.sub.2).sub.m--CONA.sub.2, A, COA, SO.sub.2A or SO.sub.3H,
[0266] R.sup.9 is H, A or benzyl,
[0267] U is CO or CH.sub.2,
[0268] V is NH or CO,
[0269] W is absent or is CO,
[0270] X is CH or N,
[0271] Y is absent or is CH.sub.2, CO or SO.sub.2,
[0272] A is unbranched, branched or cyclic alkyl having 1-20 carbon
atoms, in which one or two CH.sub.2 groups may be replaced by O or
S atoms, --CH.dbd.CH-- or --C.ident.C-- and/or 1-7H atoms may be
replaced by F,
[0273] Ar is phenyl or naphthyl, each of which is unsubstituted or
monosubstituted, disubstituted or trisubstituted by A, CF.sub.3,
Hal, OH, OA, OCF.sub.3, SO.sub.2A, SO.sub.2NH.sub.2, SO.sub.2NHA,
SO.sub.2NA.sub.2, NH.sub.2, NHA, NA.sub.2, NHCHO, NHCOA, NHCOOA,
NACOOA, NHSO.sub.2A, NHSO.sub.2Ar, COOH, COOA,
COO--(CH.sub.2).sub.m--Ar', COO--(CH.sub.2).sub.m-Het, CONH.sub.2,
CONHA, CONA.sub.2, CONHAr'CHO, COA, COAr', CH.sub.2Ar',
(CH.sub.2).sub.mNH.sub.2, (CH.sub.2).sub.mNHA,
(CH.sub.2).sub.mNA.sub.2, (CH.sub.2).sub.mNHCHO,
(CH.sub.2).sub.mNHCOA, (CH.sub.2).sub.mNHCOOA,
(CH.sub.2).sub.mNHCOO--(CH.sub.2).sub.mAr',
(CH.sub.2).sub.mNHCOO--(CH.sub.2).sub.mHet, NO.sub.2, CN,
CSNH.sub.2, C(.dbd.NH)SA, C(.dbd.NH)OA, C(.dbd.NH)NH.sub.2,
C(.dbd.NH)NHOH, C(.dbd.NH)NHCOOA or C(.dbd.NH)NHCOOAr',
[0274] Ar' is phenyl or naphthyl, each of which is unsubstituted or
monosubstituted, disubstituted or trisubstituted by A, OR.sup.9,
N(R.sup.9).sub.2, NO.sub.2, CN, Hal, NHCOA, COOR.sup.9,
CON(R.sup.9).sub.2, COR.sup.9 or S(O).sub.2A,
[0275] Het is a monocyclic or bicyclic, saturated, unsaturated or
aromatic heterocyclic radical having 1-4 N, O and/or S atoms,
bonded via N or C, which is unsubstituted or monosubstituted,
disubstituted, trisubstituted or tetrasubstituted by A, CF.sub.3,
Hal, OH, OA, OCF.sub.3, SO.sub.2A, SO.sub.2--(CH.sub.2).sub.m--Ar,
SO.sub.2NH.sub.2, SO.sub.2NHA, SO.sub.2NA.sub.2, NH.sub.2, NHA,
NA.sub.2, NHCHO, NHCOA, NHCOOA, NACOOA, NHSO.sub.2A, NHSO.sub.2Ar,
COOH, COOA, COO--(CH.sub.2).sub.m--Ar', CONH.sub.2, CONHA, COA,
COAr', CH.sub.2NH.sub.2, CH.sub.2NHA, CH.sub.2NHCHO, CH.sub.2NHCOA,
CH.sub.2NHCOOA, NO.sub.2, CN, CSNH.sub.2, C(.dbd.NH)SA,
C(.dbd.NH)OA, C(.dbd.NH)NH.sub.2, C(.dbd.NH)NHOH, C(.dbd.NH)NHCOOA,
C(.dbd.NH)COOAr' and/or carbonyl oxygen,
[0276] Py is 2-, 3- or 4-pyridyl, each of which is unsubstituted or
monosubstituted or polysubstituted by A, Hal, CN, CONH.sub.2,
CONHA, COOH, COOA, CH.sub.2NH.sub.2, CH.sub.2NHA, CH.sub.2NHCHO,
CH.sub.2NHCOA, CH.sub.2NHCOOA, CH.sub.2OH, CH.sub.2OA, CH.sub.2OAr,
CH.sub.2OCOA, NO.sub.2, NH.sub.2, NHA or NA.sub.2,
[0277] Hal is F, Cl, Br or I,
[0278] n is 1 or 2,
[0279] m is 0, 1 or 2,
[0280] p is 2, 3 or 4,
[0281] and their pharmaceutically tolerated salts and solvates,
[0282] k) compounds of the formula I 31
[0283] in which
[0284] R.sup.1 is H, Cl, F, OH, OA, O--(CH.sub.2).sub.n--Ar,
NH.sub.2, NHCOA, NHCOOA, NH--(CH.sub.2).sub.n--Ar, CN, CONH.sub.2,
CSNH.sub.2, C(.dbd.NH)SA, C(.dbd.NH)NH.sub.2,
C(.dbd.NH--OH)--NH.sub.2, C(.dbd.NH--O--COA)-NH.sub.2,
C(.dbd.NH--O--COAr)--NH.sub.2, C(.dbd.NH--O--COHet)-NH.sub.2,
C(.dbd.NH)--OA, C(.dbd.NH)NHNH.sub.2, C(.dbd.NH)NHNHA,
C(.dbd.NH)NH--COOA, C(.dbd.NH)NH--COA,
C(.dbd.NH)NH--COO--(CH.sub.2).sub.m--Ar,
C(.dbd.NH)NH--COO--(CH.sub.2).su- b.m-Het, NH--C(.dbd.NH)NH.sub.2,
NH--C(.dbd.NH)NH--COOA, NHC(.dbd.NH)NH--COO--(CH.sub.2).sub.m--Ar,
32
[0285] R.sup.2, R.sup.2'
[0286] and R.sup.2" are each, independently of one another, H, A,
CF.sub.3, Cl, F, COA, COOH, COOA, CONH.sub.2, CONHA, CONA.sub.2,
CH.sub.2NH.sub.2, CH.sub.2NHCOA, CH.sub.2NHCOOA, OH, OA, OCF.sub.3,
NO.sub.2, SO.sub.2A, SO.sub.2NH.sub.2, SO.sub.2NHA or
SO.sub.2NA.sub.2,
[0287] R.sup.3 is A, (CH.sub.2).sub.n--Ar or
(CH.sub.2).sub.n-Het,
[0288] R.sup.4 is A,
[0289] R.sup.3 and R.sup.4 together are alternatively
(CH.sub.2).sub.p, (CH.sub.2).sub.n--N(R.sup.8)--(CH.sub.2).sub.2,
(CH.sub.2).sub.2--CH(NH.s- ub.2)--(CH.sub.2).sub.2--,
(CH.sub.2).sub.2--CH(NH--COOA)-(CH.sub.2).sub.2- --,
(CH.sub.2).sub.2--CH(NH--CH.sub.2--COOA)-(CH.sub.2).sub.2--,
(CH.sub.2).sub.2--CH[NH--CH(A)-COOA]-(CH.sub.2).sub.2--,
(CH.sub.2).sub.2--O--(CH.sub.2).sub.2,
(CH.sub.2).sub.2--S(O).sub.m--(CH.- sub.2).sub.2 or 33
[0290] R.sup.5, R.sup.5', R.sup.5"
[0291] R.sup.5'" and R.sup.5"" are each, independently of one
another, (CH.sub.2).sub.n--COOH, (CH.sub.2).sub.n--COOA,
(CH.sub.2).sub.n--COO--(C- H.sub.2).sub.m--Ar,
(CH.sub.2).sub.n--COO--(CH.sub.2).sub.m-Het, Ar, Py or R.sup.2,
[0292] R.sup.6 is OH, A or Ar,
[0293] R.sup.7, R.sup.7', R.sup.7"
[0294] and R.sup.7'" are each, independently of one another, H,
Hal, OH, OA, COOH, COOA, COO(CH.sub.2).sub.mAr, CONH.sub.2, CONHA
or CONA.sub.2,
[0295] R.sup.8 is H, A, COA, COOA, (CH.sub.2).sub.n--COOH,
(CH.sub.2).sub.m--COOA, COO--(CH.sub.2).sub.m--Ar,
COO--(CH.sub.2).sub.m-Het,
(CH.sub.2).sub.n--COO--(CH.sub.2).sub.m--Ar,
(CH.sub.2).sub.n--COO--(CH.sub.2).sub.m-Het,
(CH.sub.2).sub.m--CONH.sub.2- , (CH.sub.2).sub.m--CONHA,
(CH.sub.2).sub.m--CONA.sub.2, SO.sub.2A or SO.sub.3H,
[0296] R.sup.9 is H, A or benzyl,
[0297] U is CO or CH.sub.2,
[0298] V is NH or CO,
[0299] W is absent or is CO,
[0300] X is CH or N,
[0301] Y is absent or is CH.sub.2, CO or SO.sub.2,
[0302] A is unbranched, branched or cyclic alkyl having 1-20 carbon
atoms, in which one or two CH.sub.2 groups may be replaced by O or
S atoms, --CH.dbd.CH-- or --C.ident.C-- and/or 1-7H atoms may be
replaced by F,
[0303] Ar is phenyl or naphthyl, each of which is unsubstituted or
monosubstituted, disubstituted or trisubstituted by A, CF.sub.3,
Hal, OH, OA, OCF.sub.3, SO.sub.2A, SO.sub.2NH.sub.2, SO.sub.2NHA,
SO.sub.2NA.sub.2, NH.sub.2, NHA, NA.sub.2, NHCHO, NHCOA, NHCOOA,
NACOOA, NHSO.sub.2A, NHSO.sub.2Ar, COOH, COOA,
COO--(CH.sub.2).sub.m--Ar', COO--(CH.sub.2).sub.m-Het, CONH.sub.2,
CONHA, CONA.sub.2, CONHAr', CHO, COA, COAr', CH.sub.2Ar',
(CH.sub.2).sub.mNH.sub.2, (CH.sub.2).sub.mNHA,
(CH.sub.2).sub.mNA.sub.2, (CH.sub.2).sub.mNHCHO,
(CH.sub.2).sub.mNHCOA, (CH.sub.2).sub.mNHCOOA,
(CH.sub.2).sub.mNHCOO--(CH.sub.2).sub.mAr',
(CH.sub.2).sub.mNHCOO--(CH.sub.2).sub.mHet, NO.sub.2, CN,
CSNH.sub.2, C(.dbd.NH)SA, C(.dbd.NH)OA, C(.dbd.NH)NH.sub.2,
C(.dbd.NH)NHOH, C(.dbd.NH)NHCOOA or C(.dbd.NH)NHCOOAr',
[0304] Ar' is phenyl or naphthyl, each of which is unsubstituted or
monosubstituted, disubstituted or trisubstituted by A, OR.sup.9,
N(R.sup.9).sub.2, NO.sub.2, CN, Hal, NHCOA, COOR.sup.9,
CON(R.sup.9).sub.2, COR.sup.9 or S(O).sub.2A,
[0305] Het is a monocyclic or bicyclic, saturated, unsaturated or
aromatic heterocyclic radical having 1-4 N, O and/or S atoms,
bonded via N or C, which is unsubstituted or monosubstituted,
disubstituted, trisubstituted or tetrasubstituted by A, CF.sub.3,
Hal, OH, OA, OCF.sub.3, SO.sub.2A, SO.sub.2--(CH.sub.2).sub.m--Ar,
SO.sub.2NH.sub.2, SO.sub.2NHA, SO.sub.2NA.sub.2, NH.sub.2, NHA,
NA.sub.2, NHCHO, NHCOA, NHCOOA, NACOOA, NHSO.sub.2A, NHSO.sub.2Ar,
COOH, COOA, COO--(CH.sub.2).sub.m--Ar', CONH.sub.2, CONHA, COA,
COAr', CH.sub.2NH.sub.2, CH.sub.2NHA, CH.sub.2NHCHO, CH.sub.2NHCOA,
CH.sub.2NHCOOA, NO.sub.2, CN, CSNH.sub.2, C(.dbd.NH)SA,
C(.dbd.NH)OA, C(.dbd.NH)NH.sub.2, C(.dbd.NH)NHOH, C(.dbd.NH)NHCOOA,
C(.dbd.NH)COOAr' and/or carbonyl oxygen,
[0306] Py is 2-, 3- or 4-pyridyl, each of which is unsubstituted or
monosubstituted or polysubstituted by A, Hal, CN, CONH.sub.2,
CONHA, COOH, COOA, CH.sub.2NH.sub.2, CH.sub.2NHA, CH.sub.2NHCHO,
CH.sub.2NHCOA, CH.sub.2NHCOOA, CH.sub.2OH, CH.sub.2OA, CH.sub.2OAr,
CH.sub.2OCOA, NO.sub.2, NH.sub.2, NHA or NA.sub.2,
[0307] Hal is F, Cl, Br or I,
[0308] n is 1 or 2,
[0309] m is 0, 1 or 2,
[0310] p is 2, 3, 4-or 5,
[0311] and their pharmaceutically tolerated salts and solvates,
[0312] l) compounds of the formula I 34
[0313] in which
[0314] R is CN, CH.sub.2NH.sub.2, --NH--C(.dbd.NH)--NH.sub.2,
--CO--N.dbd.C(NH.sub.2).sub.2, --C(.dbd.NH)--NH.sub.2, which may
also be monosubstituted by Ar', OH, O--COA, O--COAr, OCOOA,
OCOO(CH.sub.2).sub.nN(A).sub.2, --COO(CH.sub.2).sub.nNA.sub.2,
OCOO(CH.sub.2).sub.mHet, COO--(CH.sub.2).sub.m-Het,
CO--C(A).sub.2--R.sup.3, COOA, COSA, COSAr, COOAr, COOAr', COA,
COAr, COAr' or by a conventional amino-protecting group, or is
35
[0315] R.sup.1 is R.sup.4, Ar, Ar' or X,
[0316] R.sup.2 is phenyl which monosubstituted by SA, SOA,
SO.sub.2A, SONHA, SO.sub.2NHA, CF.sub.3, COOA, CH.sub.2NHA, CN or
OA,
[0317] R.sup.3 36
[0318] R.sup.4 is alkyl having 1-20 carbon atoms, in which one or
two CH.sub.2 groups may be replaced by O or S atoms and/or by
--CH.dbd.CH-- groups and/or in addition 1-7H atoms may be replaced
by F,
[0319] A is H or alkyl having 1-20 carbon atoms,
[0320] A' is alkyl having 1-10 carbon atoms,
[0321] Ar is phenyl or naphthyl, each of which is unsubstituted or
monosubstituted, disubstituted or trisubstituted by A', OH, OA',
NH.sub.2, NHA', NA'.sub.2, NO.sub.2, CF.sub.3, CN, Hal, NHCOA,
COOA, CONH.sub.2, CONHA', CONA'.sub.2, SA, SOA, SO.sub.2A,
[0322] SO.sub.2NH.sub.2, SO.sub.2NHA' or SO.sub.2NA'.sub.2,
[0323] Ar' is (CH.sub.2).sub.n--Ar,
[0324] Het is a monocyclic or bicyclic, saturated, unsaturated or
aromatic heterocyclic radical having from 1 to 4 N, O and/or S
atoms, which may be unsubstituted or monosubstituted, disubstituted
or trisubstituted by A', OA', NH.sub.2, NHA', NA'.sub.2, NO.sub.2,
CN, Hal, NHCOA', NHSO.sub.2A', COOA, CONH.sub.2, CONHA',
CONA'.sub.2, COA, SO.sub.2NH.sub.2, SA', SOA', SO.sub.2A' and/or
carbonyl oxygen,
[0325] X is (CH.sub.2).sub.nY,
[0326] Y 37
[0327] Hal is F, Cl, Br or I,
[0328] n is 1, 2, 3, 4, 5 or 6,
[0329] m is 0 or 1,
[0330] and their pharmaceutically tolerated salts and solvates,
[0331] m) compounds of the formula I 38
[0332] in which
[0333] R is CH.sub.2NH.sub.2, --CO--N.dbd.C(NH.sub.2).sub.2,
--NH--C(.dbd.NH)--NH.sub.2 or --C(.dbd.NH)--NH.sub.2, which may
also be monosubstituted by OH, --OCOOA, --OCOO(CH.sub.2).sub.nNAA',
--COO(CH.sub.2).sub.nNAA', --OCOO(CH.sub.2).sub.m-Het,
--COO(CH.sub.2).sub.m-Het, --CO--CAA'--R.sup.3,
--COO--CAA'--R.sup.3, COOA, COSA, COOAr, COOAr' or by a
conventional amino-protecting group, or is 39
[0334] R.sup.1 is unbranched, branched or cyclic alkyl having 1-20
carbon atoms, in which one or two CH.sub.2 groups may be replaced
by O or S atoms, or is Ar, Ar' or X,
[0335] R.sup.2 is phenyl which is monosubstituted by S(O).sub.pA,
S(O).sub.pNHA, CF.sub.3, COOA, CH.sub.2NHA, CN or OA,
[0336] R.sup.3 40
[0337] Ar is phenyl or naphthyl, each of which is unsubstituted or
monosubstituted, disubstituted or trisubstituted by A, OA, NAA',
NO.sub.2, CF.sub.3, CN, Hal, NHCOA, COOA, CONAA', S(O).sub.pA or
S(O).sub.pNAA',
[0338] Ar' is --(CH.sub.2).sub.n--Ar,
[0339] A is H or unbranched, branched or cyclic alkyl having 1-20
carbon atoms,
[0340] A' is unbranched, branched or cyclic alkyl having 1-10
carbon atoms,
[0341] Het is a monocyclic or bicyclic, saturated, unsaturated or
aromatic heterocyclic radical having from 1 to 4 N, O and/or S
atoms, bonded via N or C, which may be unsubstituted or substituted
by A,
[0342] X is --(CH.sub.2).sub.n--Y,
[0343] Y 41
[0344] Hal is F, Cl, Br or I,
[0345] m is 0 or 1,
[0346] n is 1, 2, 3, 4, 5 or 6,
[0347] p is 0, 1 or 2,
[0348] and their pharmaceutically tolerated salts and solvates,
[0349] n) compounds of the formula I 42
[0350] in which:
[0351] R.sup.1 is phenyl or naphthyl, each of which is substituted
by --C(.dbd.NH)NH.sub.2, which may also be monosubstituted by
--COA, --CO--[C(R.sup.6).sub.2--Ar', --COOA, --OH or by a
conventional amino-protecting group, --NHC(.dbd.NH)--NH.sub.2,
43
[0352] and which may optionally be substituted by -A, --OR.sup.5,
--N(R.sup.5).sub.2, --NO.sub.2, --CN, -Hal, --NR.sup.5COA,
--NR.sup.5COAr', --NR.sup.5SO.sub.2A, --NR.sup.5SO.sub.2Ar',
--COOR.sup.5, --CON(R.sup.5).sub.2, --CONR.sup.5Ar', --COR.sup.6,
--COAr' or S(O).sub.nA;
[0353] R.sup.2 is --N(R.sup.5).sub.2, --NR.sup.5COA, --NR.sup.5COAr
or --NR.sup.5COOR.sup.5,
[0354] R.sup.3 and
[0355] R.sup.4, independently of one another, are --H, -A,
--OR.sup.5, --N(R.sup.5).sub.2, --NO.sub.2, --CN, -Hal,
--NR.sup.5COA, --NR.sup.5COAr, --NR.sup.5SO.sub.2A,
--NR.sup.5SO.sub.2Ar', --COOR.sup.5, --CON(R.sup.5).sub.2,
--CONR.sup.5Ar', --COR.sup.6, --COAr', --S(O)Ar' or
S(O).sub.nA;
[0356] R.sup.5-- is H, -A, --C(R.sup.6R.sup.7)Ar' or
--C(R.sup.6R.sup.7)Het;
[0357] R.sup.6 and
[0358] R.sup.7, independently of one another, are --H, -A or
--(CH.sub.2).sub.1--Ar';
[0359] R.sup.8 is H or A;
[0360] X is --O--, --NR.sup.5--, --CONR.sup.5--, --N(SO.sub.2Ar)--
or --N(SO.sub.2Het)-;
[0361] W is --(CR.sup.6R.sup.7).sub.n--, --OCR.sup.6R.sup.7--,
1,3-phenylene, 1,3-phenylene- --C(R.sup.6).sub.2--, 1,4-phenylene
or 1,4-phenylene-C(R.sup.6).sub.2--;
[0362] V is --(C(R.sup.6).sub.2).sub.m--;
[0363] A is alkyl having from 1 to 20 carbon atoms, in which one or
two CH.sub.2 groups may be replaced by O or S atoms or by
--CH.dbd.CH-- groups and in addition by from 1 to 7H atoms may be
replaced by F;
[0364] Ar' is phenyl or naphthyl, each of which is unsubstituted or
monosubstituted, disubstituted or trisubstituted by -A, --Ar',
-Het, --OR.sup.5, --N(R.sup.5).sub.2, --NO.sub.2, --CN, -Hal,
--NR.sup.5COA, --NR.sup.5COAr, --NR.sup.5SO.sub.2A,
--NR.sup.5SO.sub.2Ar', --COOR.sup.5, --CON(R.sup.5).sub.2,
--CONR.sup.5Ar', --COR.sup.6, --COAr' or --S(O).sub.nA,
[0365] Ar' is phenyl or naphthyl, each of which is unsubstituted or
monosubstituted, disubstituted or trisubstituted by -A, --OR.sup.6,
--N(R.sup.6).sub.2, --NO.sub.2, --CN, -Hal, --NR.sup.6COA,
--NR.sup.6SO.sub.2A, --COOR, --CON(R.sup.6).sub.2--COR.sup.6,
--SO.sub.2NR.sup.6 or --S(O).sub.nA,
[0366] Het is a monocyclic or bicyclic, saturated, unsaturated or
aromatic heterocyclic radical having from 1 to 4 N, O and/or S
atoms, bonded via N or C, which may be unsubstituted or
monosubstituted, disubstituted or trisubstituted by -A, --OR.sup.6,
--N(R.sup.6).sub.2, --NO.sub.2, --CN, -Hal, --NR.sup.6COA,
--NR.sup.6SO.sub.2A, --COOR.sup.6, --CON(R.sup.6).sub.2,
--COR.sup.6, --SO.sub.2NR.sup.6, --S(O).sub.nA and/or carbonyl
oxygen;
[0367] Hal is --F, --Cl, --Br or --I;
[0368] I is 0, 1, 2, 3, 4 or 5;
[0369] m is 0 or 1;
[0370] n is 0, 1 or 2;
[0371] and their pharmaceutically tolerated salts and solvates,
[0372] o) compounds of the formula I 44
[0373] in which
[0374] R.sup.1 is phenyl or naphthyl, each of which is substituted
by --C(.dbd.NH)NH.sub.2, which may also be monosubstituted by
--COA, --CO-[C(R.sup.7).sub.2].sub.n--Ar', --COOA, --OH or by a
conventional amino-protecting group, --NHC(.dbd.NH)--NH.sub.2,
--CON.dbd.C(NH.sub.2).s- ub.2, 45
[0375] and which may optionally be substituted by -A, --OR.sup.5,
--N(R.sup.5).sub.2, --NO.sub.2, --CN, -Hal, --NR.sup.5COA,
--NR.sup.5COAr', --NR.sup.5SO.sub.2A, --NR.sup.5SO.sub.2Ar',
--COOR.sup.5, --CON(R.sup.5).sub.2, --COR.sup.7, --COAr' or
S(O).sub.nA;
[0376] R.sup.2 is --S(O).sub.nA, --CF.sub.3, --COOR or --OA;
[0377] R.sup.3 and
[0378] R.sup.4, independently of one another, are --H, -A,
--OR.sup.5, --N(R.sup.5).sub.2A, --NO.sub.2, --CN, -Hal,
--NR.sup.5COA, --NR.sup.5COAr', --NR.sup.5SO.sub.2A,
--NR.sup.5SO.sub.2Ar', --COOR.sup.5, --CON(R.sup.5).sub.2,
--CONR.sup.5Ar, --COR.sup.7, --COAr' or --S(O).sub.nA;
[0379] R.sup.5 and
[0380] R.sup.6, independently of one another, are --H, -A,
--[C(R.sup.7R.sup.8)].sub.nAr' or
--[C(R.sup.7R.sup.8)].sub.nHet;
[0381] R.sup.7 and
[0382] R.sup.8, independently of one another, are --H or -A;
[0383] W is
--[C(R.sup.5R.sup.6)].sub.mCONR.sup.5[C(R.sup.5R.sup.6)].sub.1- --
or --OC(R.sup.5R.sup.6)CONR.sup.5[C(R.sup.5R.sup.6)].sub.1--;
[0384] A is alkyl having from 1 to 20 carbon atoms, in which one or
two CH.sub.2 groups may be replaced by O or S atoms or by
--CH.dbd.CH-- groups and in addition from 1 to 7H atoms may be
replaced by --F;
[0385] Ar is phenyl or naphthyl, each of which is unsubstituted or
monosubstituted, disubstituted or trisubstituted by -A, --Ar',
-Het, --OR.sup.5, --N(R.sup.5).sub.2, --NO.sub.2, --CN, -Hal,
--NR.sup.5COA, --NR.sup.5COAr, --NR.sup.5SO.sub.2A,
--NR.sup.5SO.sub.2Ar', --COOR.sup.5, --CON(R.sup.5).sub.2,
--CONR.sup.5Ar', --COR.sup.7, --COAr', --SO.sub.2NR.sup.5,
--S(O).sub.nAr' or --S(O).sub.nA;
[0386] Ar' is phenyl or naphthyl, each of which is unsubstituted or
monosubstituted, disubstituted or trisubstituted by -A, --OR.sup.7,
--N(R.sup.7).sub.2, --NO.sub.2, --CN, -Hal, --NR.sup.7COA,
--NR.sup.7SO.sub.2A, --COOR.sup.7, --CON(R.sup.7).sub.2,
--COR.sup.7, --SO.sub.2NR.sup.7 or --S(O).sub.nA;
[0387] Het is a monocyclic or bicyclic, saturated, unsaturated or
aromatic heterocyclic radical having from 1 to 4 N, O and/or S
atoms, bonded via N or C, which may be unsubstituted or
monosubstituted, disubstituted or trisubstituted by -A, --OR.sup.7,
--N(R.sup.7).sub.2, --NO.sub.2, --CN, -Hal, --NR.sup.7COA,
--NR.sup.7SO.sub.2A, --COOR.sup.7, --CON(R.sup.7).sub.2,
--COR.sup.7, --SO.sub.2NR.sup.7--S(O).sub.nA and/or carbonyl
oxygen;
[0388] Hal is --F, --Cl, --Br or --I;
[0389] I is 0 or 1;
[0390] m is 1 or 2;
[0391] n is 0, 1 or 2;
[0392] and their pharmaceutically tolerated salts and solvates,
[0393] p) compounds of the formula I 46
[0394] in which
[0395] R.sup.1 is H, Cl, F, OH, OA, O--(CH.sub.2).sub.n--Ar,
NH.sub.2, NHCOA, NHCOOA, NH--(CH.sub.2).sub.n--Ar, CN, CONH.sub.2,
CSNH.sub.2, C[NH]SA, C[NH]NH.sub.2, C[NH]NHA, C[NH]NOH, C[NH]NOA,
C[NH]NOCOA, C[NH]NOCOAr, C[NH]OA, C[NH]NHNH.sub.2, C[NH]NHNHA,
C[NH]NHCOOA, C[NH]NHCOA C[NH]NHCOO--(CH.sub.2).sub.m--Ar,
C[NH]NHCOO--(CH.sub.2).sub.m- -Het, NHC[NH]NH.sub.2, NHC[NH]NHCOOA,
NHC[NH]NHCOO--(CH.sub.2).sub.m--Ar or Q1,
[0396] R.sup.2 is H or one or more A, CF.sub.3, Br, Cl, F, COA,
COOH, COOA, CONH.sub.2, CONHA, CONA.sub.2, CH.sub.2NH.sub.2,
CH.sub.2NHCOA, CH.sub.2NHCOOA, NHSO.sub.2A, OH, OA, OCF.sub.3,
NO.sub.2, SO.sub.2A, SO.sub.2NH.sub.2 or SO.sub.2NHA,
[0397] R.sup.3 is H, COH, COA, COCF.sub.3, COOA or SO.sub.2A
[0398] R.sup.4 is H, A, --(CH.sub.2).sub.r--Ar,
--(CH.sub.2).sub.n-Het, --(CH.sub.2).sub.m--COOR.sup.7,
--(CH.sub.2).sub.m--CONHR.sup.7, --(CH.sub.2).sub.n--S(O).sub.mA,
--(CH.sub.2).sub.o--NH.sub.2, --(CH.sub.2).sub.o--NHCOOA,
--(CH.sub.2).sub.o--NHCOA, --(CH.sub.2).sub.o--NHAr,
--(CH.sub.2).sub.o--NHC[NH]NH.sub.2,
--(CH.sub.2).sub.o--(C[A]OH)-A, --(CH.sub.2).sub.o--OH,
--(CH.sub.2).sub.o--OA, --(CH.sub.2).sub.o--OAr,
--(CH.sub.2).sub.o-OHet, --(CH.sub.2).sub.o--OCOOA,
--(CH.sub.2).sub.o--OCOA, --(CH.sub.2).sub.o--OCOAr, Ar or Het,
[0399] R.sup.5 is --(CH.sub.2).sub.n--COOH,
--(CH.sub.2).sub.n--COOA,
--(CH.sub.2).sub.n--COO(CH.sub.2).sub.nAr, Ar, Py or R.sup.2,
[0400] R.sup.6 is OH, A or Ar,
[0401] R.sup.7 is H, A, Ar or Het,
[0402] U is CO or CH.sub.2,
[0403] V is NH, CO or O,
[0404] w is a bond or CO,
[0405] X is CH or N,
[0406] Y is a bond or CH.sub.2, CO or SO.sub.2,
[0407] n is 1 or 2,
[0408] m is 0, 1 or 2,
[0409] o is 1, 2, 3, 4 or 5,
[0410] p is 2, 3 or 4,
[0411] A is alkyl having 1-20 carbon atoms (linear, branched or
cyclic), in which one or two CH.sub.2 groups may be replaced by O
or S atoms or by --CH.dbd.CH-- or --C.ident.C-- groups and in
addition 1-7H atoms may be replaced by F,
[0412] Ar is phenyl or naphthyl, each of which is unsubstituted or
monosubstituted, disubstituted or trisubstituted by A, CF.sub.3,
Hal, OA, OCF.sub.3, SO.sub.2A, SO.sub.2NH.sub.2, SO.sub.2NHA,
SO.sub.2NA.sub.2, NH.sub.2, NHA, NA.sub.2, NHCHO, NHCOA, NHCOOA,
NACOOA, NHSO.sub.2A, NHSO.sub.2Ar, COOH, COOA,
COO--(CH.sub.2).sub.m--Ar, COO--(CH.sub.2).sub.m-Het CONH.sub.2,
CONHA, CONA.sub.2, CONHAr, COA, COAr, CH.sub.2Ar,
--(CH.sub.2).sub.m--NH.sub.2, --(CH.sub.2).sub.m--NHA,
--(CH.sub.2).sub.m--NA.sub.2, --(CH.sub.2).sub.m--NHCHO,
--(CH.sub.2).sub.m--NHCOA, --(CH.sub.2).sub.m--NHCOOA
--(CH.sub.2).sub.m--NHCOO--(CH.sub.2).sub.mAr,
--(CH.sub.2).sub.m--NHCOO-- -(CH.sub.2).sub.m-Het,
--(CH.sub.2).sub.m-Hal, --(CH.sub.2).sub.m-Het, NO.sub.2, CN,
CSNH.sub.2, C[NH]SA, C[NH]OA, C[NH]NH.sub.2, C[NH]NHOH, C[NH]NHCOOA
or C[NH]NHCOOAr,
[0413] Het is a monocyclic or bicyclic, saturated, unsaturated or
aromatic heterocyclic radical having from 1 to 4 N, O and/or S
atoms, bonded via N or C, which may be unsubstituted or
monosubstituted, disubstituted, trisubstituted or tetrasubstituted
by A, CF.sub.3, Hal, OH, OA, SO.sub.2A,
SO.sub.2--(CH.sub.2).sub.m--Ar, SO.sub.2NH.sub.2, SO.sub.2NHA,
SO.sub.2NA.sub.2, NH.sub.2, NHA, NA.sub.2, NHCHO, NHCOA, NHCOOA,
NHSO.sub.2A, NHSO.sub.2Ar, COOH, COOA, COO--[CH.sub.2].sub.m--Ar,
CONH.sub.2, CONHA, COA, COAr, CH.sub.2NH.sub.2, CH.sub.2NHA,
CH.sub.2NHCHO, CH.sub.2NHCOA, CH.sub.2NHCOOA, NO.sub.2, CN,
CSNH.sub.2, C[NH]SA, C[NH]OA, C[NH]NH.sub.2, C[NH]NHOH,
C[NH]NHCOOA, C[NH]NHCOOAr and/or carbonyl oxygen,
[0414] Py is 2-, 3- and/or 4-pyridyl, unsubstituted or
monosubstituted or polysubstituted by A, Hal, CN, CONH.sub.2,
CONHA, COOH, COOA, CH.sub.2NH.sub.2, CH.sub.2NHA, CH.sub.2NHCHO,
CH.sub.2NHCOA, CH.sub.2NHCOOA, CH.sub.2OH, CH.sub.2OA, CH.sub.2OAr,
CH.sub.2OCOA, NO.sub.2, NH.sub.2, NHA or NA.sub.2,
[0415] Hal is F, Cl, Br or I,
[0416] and their pharmaceutically tolerated salts and solvates,
[0417] q) compounds of the formula I 47
[0418] in which
[0419] R.sup.1 is --(CH.sub.2).sub.n--NH.sub.2,
--CON.dbd.C(NH.sub.2).sub.- 2, --NHC(.dbd.NH)--NH.sub.2 or
--C(.dbd.NH)--NH.sub.2, which may also be monosubstituted by --OH,
--OCOOA, --OCOO(CH.sub.2).sub.nN(A).sub.2,
--OCOO(CH.sub.2).sub.m-Het, --CO--C(A).sub.2--R.sup.5, --COOA,
--COSA, --COOAr, --COOAr' or 48
[0420] R.sup.2 is H or COOA,
[0421] R.sup.3 is unbranched, branched or cyclic alkyl having 1-20
carbon atoms, in which one or two CH.sub.2 groups may be replaced
by O or S atoms, or is Ar, Ar', X or Hal,
[0422] R.sup.4 is phenyl which is monosubstituted by S(O).sub.kA,
S(O).sub.kNHA, CF.sub.3, COOA, CH.sub.2NHA, CN or OA,
[0423] R.sup.5 is --CHal.sub.3, --O(C.dbd.O)A or 49
[0424] Ar is phenyl or naphthyl, each of which is unsubstituted or
monosubstituted, disubstituted or trisubstituted by A, OH, OA,
NH.sub.2, NHA, NA.sub.2, NO.sub.2, CF.sub.3, CN, Hal, NHCOA, COOA,
CONH.sub.2, CONHA, CONA.sub.2, S(O).sub.nA, S(O).sub.nNH.sub.2,
S(O)NHA or S(O).sub.nNA.sub.2,
[0425] Ar' is --(CH.sub.2).sub.n--Ar,
[0426] Het is a monocyclic or bicyclic, saturated, unsaturated or
aromatic heterocyclic radical having from 1 to 4 N, O and/or S
atoms, bonded via N or C, which may be unsubstituted or substituted
by A,
[0427] A is H or unbranched, branched or cyclic alkyl having 1-20
carbon atoms,
[0428] X is --(CH.sub.2).sub.n--Y,
[0429] Y is COOA, 50
[0430] Hal is F, Cl, Br or I,
[0431] n is 1, 2, 3, 4, 5 or 6,
[0432] m is 0 or 1,
[0433] k is 0, 1 or 2,
[0434] l is 0, 1, 2, 3 or 4,
[0435] and their pharmaceutically tolerated salts and solvates,
[0436] r) compounds of the formula I 51
[0437] in which
[0438] -D=E- is --N.dbd.C(NH.sub.2)-- or --C(NH.sub.2).dbd.N--,
[0439] R.sup.1 and R.sup.2, independently of one another, are H, A,
OR.sup.6, N(R.sup.6).sub.2, NO.sub.2, CN, Hal, NR.sup.6COA,
NR.sup.6COAr', NR.sup.6SO.sub.2A, NR.sup.6SO.sub.2Ar', COOR.sup.6,
CON(R.sup.6).sub.2, CONR.sup.6Ar', COR.sup.7, COAr' or
S(O).sub.nA,
[0440] R.sup.3 is SO.sub.2(NR.sup.6).sub.2, S(O).sub.nA, CF.sub.3,
COOR.sup.6, OA or CN,
[0441] R.sup.4 and R.sup.5, independently of one another, are H, A,
OR.sup.6, N(R.sup.6).sub.2, NO.sub.2, CN, Hal, NR.sup.6COA,
NR.sup.6COAr', NR.sup.6SO.sub.2A, NR.sup.6SO.sub.2Ar', COOR.sup.6,
CON(R.sup.6).sub.2, CONR.sup.6Ar', COR.sup.7, COAr' or
S(O).sub.nA,
[0442] R.sup.6 is H, A, [C(R.sup.7).sub.2].sub.nAr' or
[C(R.sup.7).sub.2].sub.nHet,
[0443] R.sup.7 is H or A,
[0444] W is
CONR.sup.6C(R.sup.6).sub.2CONR.sup.6[C(R.sup.6).sub.2].sub.1--- ,
--NR.sup.6C(R.sup.6).sub.2CONR.sup.6 [C(R.sup.6).sub.2].sub.1--,
--[C(R.sup.6).sub.2].sub.mCONR.sup.6[C(R.sup.6).sub.2].sub.1-- or
--OC(R.sup.6).sub.2CONR.sup.6[C(R.sup.6).sub.2].sub.1--,
[0445] A is alkyl having 1-20 carbon atoms, in which one or two
CH.sub.2 groups may be replaced by O or S atoms or by --CH.dbd.CH--
groups and in addition 1-7H atoms may be replaced by F,
[0446] Ar is phenyl or naphthyl, each of which is unsubstituted or
monosubstituted, disubstituted or trisubstituted by A, Ar', Het,
OR.sup.6, N(R.sup.6).sub.2, NO.sub.2, CN, Hal, NR.sup.6COA,
NR.sup.6COAr', NR.sup.6SO.sub.2A, NR.sup.6SO.sub.2Ar', COOR.sup.6,
CON(R.sup.6).sub.2, CONR.sup.6Ar', COR.sup.7, COAr',
SO.sub.2NR.sup.6, S(O).sub.nAr' or S(O).sub.nA,
[0447] Ar' is phenyl or naphthyl, each of which is unsubstituted or
monosubstituted, disubstituted or trisubstituted by A, OR.sup.7,
N(R.sup.7).sub.2, NO.sub.2, CN, Hal, NR.sup.7COA,
NR.sup.7SO.sub.2A, COOR.sup.7, CON(R.sup.7).sub.2, COR.sup.7,
SO.sub.2NR.sup.7 or S(O).sub.nA,
[0448] Het is a monocyclic or bicyclic, saturated, unsaturated or
aromatic heterocyclic radical having from 1 to 4 N, O and/or S
atoms, bonded via N or C, which may be unsubstituted or
monosubstituted, disubstituted or trisubstituted by A, OR.sup.7,
N(R.sup.7).sub.2, NO.sub.2, CN, Hal, NR.sup.7COA,
NR.sup.7SO.sub.2A, COOR.sup.7, CON(R.sup.7).sub.2, COR.sup.7,
SO.sub.2NR.sup.7 S(O).sub.nA and/or carbonyl oxygen,
[0449] Hal is F, Cl, Br or I,
[0450] n is 0, 1 or 2,
[0451] m is 1 or 2,
[0452] l is 0 or 1,
[0453] and their pharmaceutically tolerated salts and solvates,
[0454] s) compounds of the formula I 52
[0455] in which
[0456] D is phenyl or pyridyl, each of which is unsubstituted or
monosubstituted or polysubstituted by Hal, A, OR.sup.2,
N(R.sup.2).sub.2, NO.sub.2, CN, COOR.sup.2 or
CON(R.sup.2).sub.2,
[0457] R.sup.1 is H, Ar, Het, cycloalkyl or A, which may be
substituted by OR.sup.2, SR.sup.2, N(R.sup.2).sub.2, Ar, Het,
cycloalkyl, CN, COOR.sup.2 or CON(R.sup.2).sub.2,
[0458] R.sup.2 is H or A,
[0459] E is phenylene, which may be monosubstituted or
polysubstituted by Hal, A, OR.sup.2, N(R.sup.2).sub.2, NO.sub.2,
CN, COOR.sup.2 or CON(R.sup.2).sub.2,
[0460] or is piperidine-1,4-diyl,
[0461] W is Ar, Het or N(R.sup.2).sub.2
[0462] and, if E=piperidine-1,4-diyl, is alternatively R.sup.2 or
cycloalkyl,
[0463] X is NH or O,
[0464] A is unbranched or branched alkyl having 1-10 carbon atoms,
in which one or two CH.sub.2 groups may be replaced by O or S atoms
and/or by --CH.dbd.CH-- groups and/or in addition 1-7H atoms may be
replaced by F,
[0465] Ar is phenyl which is unsubstituted or monosubstituted,
disubstituted or trisubstituted by Hal, A, OR.sup.2,
N(R.sup.2).sub.2, NO.sub.2, CN, COOR.sup.2, CON(R.sup.2,
NR.sup.2COA, NR.sup.2SO.sub.2A, COR.sup.2, SO.sub.2NR, SO.sub.3H or
S(O).sub.mA,
[0466] Het is a monocyclic or bicyclic, saturated, unsaturated or
aromatic heterocyclic radical having from 1 to 4 N, O and/or S
atoms, which may be unsubstituted or monosubstituted, disubstituted
or trisubstituted by Hal, A, OR.sup.2, N(R.sup.2).sub.2, NO.sub.2,
CN, COOR.sup.2, CON(R.sup.2).sub.2, NR.sup.2COA, NR.sup.2SO.sub.2A,
COR.sup.2, SO.sub.2NR.sup.2, SO.sub.3H or S(O).sub.mA and/or
carbonyl oxygen,
[0467] Hal is F, Cl, Br or I,
[0468] n is 0 or 1,
[0469] m is 0, 1 or 2,
[0470] and their pharmaceutically tolerated salts and solvates.
[0471] Other preferred factor Xa inhibitors are, for example, the
compounds described in the following documents:
[0472] a) in WO 97/30971, page 4, line 5, to page 13, line 19;
[0473] b) in EP 0 921 116 A1, page 2, line 1, to line 51;
[0474] c) in EP 0 540 051 B1, page 2, line 41, to page 3, line
14;
[0475] d) in EP 0 798 295 A1, page 69, line 10, to page 71, page
53;
[0476] Other preferred compounds are selected from the group
consisting of defibrotide, desirudin and lepirudin.
[0477] The invention preferably relates to a formulation comprising
[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]-p-
yrimidin-5-ylmethoxy]acetic acid and physiologically acceptable
salts and/or solvates thereof and a calcium antagonist.
[0478] Besides the free acid, the ethanolamine salt is
preferred.
[0479] Preference is given to calcium antagonists selected from the
group consisting of selective and non-selective calcium
antagonists.
[0480] Preference is given to selective calcium antagonists
selected from the group consisting of dihydropyridine derivatives,
phenylalkylamine derivatives, benzothiazepine derivatives and other
selective calcium antagonists.
[0481] Dihydropyridine derivatives are preferably selected from the
group consisting of amlodipine, felodipine, isradipine,
nicardipine, nifedipine, nimodipine, nisoldipine, nitrendipine,
lacidipine, nilvadipine, manidipine, bamidipine and
lercanidipine.
[0482] The phenylalkylamine derivatives are preferably selected
from the group consisting of verapamil and gallopamil.
[0483] The benzothiazepine derivatives are preferably
diltiazem.
[0484] The other selective calcium antagonists are preferably
mibefradil.
[0485] The non-selective calcium antagonists are preferably
selected from the group consisting of fendiline, bepridil,
lidoflazine and perhexiline.
[0486] The invention preferably relates to a formulation comprising
[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]-p-
yrimidin-5-ylmethoxy]acetic acid and physiologically acceptable
salts and/or solvates thereof and a prostaglandin or prostaglandin
derivative. Besides the free acid, the ethanolamine salt is
preferred.
[0487] Preference is given to prostaglandins or prostaglandin
derivatives selected from the group consisting of PGE.sub.0,
PGA.sub.1, PGB.sub.1, PGF.sub.1.alpha., PGA.sub.2, PGB.sub.2,
19-hydroxy-PGA.sub.1, 19-hydroxy-PGB.sub.1, 19-hydroxy-PGA.sub.2,
19-hydroxy-PGB.sub.2, PGE.sub.3, PGF.sub.3.alpha., alprostadil
(PGE.sub.1), dinoprost (PGF.sub.2), dinoprostone (PGE.sub.2),
epoprostenol sodium (PGI.sub.2; prostacyclin sodium), gemeprost,
iloprost, latanoprost, misoprostol, sulprostone, carboprost
thromethamin, dinoprost thromethamin, lipoprost, metenoprost and
tiaprost.
[0488] Particular preference is given to prostaglandins or
prostaglandin derivatives selected from the group consisting of
alprostadil (PGE.sub.1), dinoprost (PGF.sub.2), dinoprostone
(PGE.sub.2), epoprostenol sodium (PGI.sub.2; prostacyclin sodium),
gemeprost, iloprost, latanoprost, misoprostol, sulprostone,
carboprost thromethamin, dinoprost thromethamin, lipoprost,
metenoprost and tiaprost.
[0489] Particular preference is given to PGE.sub.1 or prostacyclin,
especially preferably prostacyclin.
[0490] The compounds of the formula I and also the starting
materials for their preparation are, in addition, prepared by
methods known per se, as described in the literature (for example
in the standard works, such as Houben-Weyl, Methoden der
organischen Chemie [Methods of Organic Chemistry],
Georg-Thieme-Verlag, Stuttgart), to be precise under reaction
conditions which are known and suitable for the said reactions. Use
can also be made here of variants which are known per se, but are
not mentioned here in greater detail.
[0491] In the compounds of the formula II or III, R.sup.1, R.sup.2,
R.sup.3, R.sup.4 and X have the meanings indicated, in particular
the preferred meanings indicated.
[0492] If L is a reactive esterified OH group, this is preferably
alkylsulfonyloxy having 1-6 carbon atoms (preferably
methylsulfonyloxy) or arylsulfonyloxy having 6-10 carbon atoms
(preferably phenyl- or p-tolylsulfonyloxy, further-more also
2-naphthalenesulfonyloxy).
[0493] The compounds of the formula I can preferably be obtained by
reacting compounds of the formula II with compounds of the formula
III.
[0494] If desired, the starting materials can also be formed in
situ by not isolating them from the reaction mixture, but instead
immediately converting them further into the compounds of the
formula I.
[0495] On the other hand, it is possible to carry out the reaction
stepwise.
[0496] The starting compounds of the formulae II and III are
generally known. If they are not known, they can be prepared by
methods known per se. Compounds of the formula II can be prepared
by methods known from the literature, for example from
4-amino-3-alkoxycarbonylpyrazoles by cyclisation using nitrites and
subsequent reaction of the cyclisation products with phosphorus
oxychloride (analogously to Houben Weyl E9b/2).
[0497] In detail, the reaction of the compounds of the formula II
with the compounds of the formula III is carried out in the
presence or absence of an inert solvent at temperatures between
about -20 and about 1500, preferably between 20 and
100.degree..
[0498] The addition of an acid-binding agent, for example an alkali
or alkaline earth metal hydroxide, carbonate or bicarbonate or
another salt of a weak acid of the alkali or alkaline earth metals,
preferably of potassium, sodium or calcium, or the addition of an
organic base, such as triethylamine, dimethylamine, pyridine or
quinoline or of an excess of the amine component, may be
favourable.
[0499] Examples of suitable inert solvents are hydrocarbons, such
as hexane, petroleum ether, benzene, toluene or xylene; chlorinated
hydrocarbons, such as trichloroethylene, 1,2-dichloroethane,
tetrachloromethane, chloroform or dichloromethane; alcohols, such
as methanol, ethanol, isopropanol, n-propanol, n-butanol or
tert-butanol; ethers, such as diethyl ether, diisopropyl ether,
tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene
glycol monomethyl or monoethyl ether or ethylene glycol dimethyl
ether (diglyme); ketones, such as acetone or butanone; amides, such
as acetamide, dimethylacetamide, N-methylpyrrolidone or
dimethylformamide (DMF); nitriles, such as acetonitrile;
sulfoxides, such as dimethyl sulfoxide (DMSO); nitro compounds,
such as nitromethane or nitrobenzene; esters, such as ethyl
acetate, or mixtures of the said solvents.
[0500] It is furthermore possible to convert a radical X in a
compound of the formula I into another radical X, for example by
hydrolysing an ester or a cyano group to give a COOH group.
[0501] Ester groups can be saponified, for example, using NaOH or
KOH in water, water/THF or water/dioxane at temperatures between 0
and 100.degree.. Carboxylic acids can be converted into the
corresponding carboxylic acid chlorides, for example using thionyl
chloride, and these can be converted into carboxamides. Elimination
of water therefrom in a known manner gives carbonitriles.
[0502] An acid of the formula I can be converted into the
associated acid-addition salt using a base, for example by reaction
of equivalent amounts of the acid and the base in an inert solvent,
such as ethanol, followed by evaporation. Suitable bases for this
reaction are, in particular, those which give physiologically
acceptable salts.
[0503] Thus, the acid of the formula I can be converted into the
corresponding metal salt, in particular alkali metal or alkaline
earth metal salt, or into the corresponding ammonium salt using a
base (for example sodium hydroxide, potassium hydroxide, sodium
carbonate or potassium carbonate). Also suitable for this reaction
are, in particular, organic bases which give physiologically
acceptable salts, such as, for example, ethanolamine.
[0504] On the other hand, a base of the formula I can be converted
into the associated acid-addition salt using an acid, for example
by reaction of equivalent amounts of the base and the acid in an
inert solvent, such as ethanol, followed by evaporation. Suitable
acids for this reaction are, in particular, those which give
physiologically acceptable acids. Thus, it is possible to use
inorganic acids, for example sulfuric acid, nitric acid, hydrohalic
acids, such as hydrochloric acid or hydrobromic acid, phosphoric
acids, such as orthophosphoric acid, or sulfamic acid, furthermore
organic acids, in particular aliphatic, alicyclic, araliphatic,
aromatic or heterocyclic monobasic or polybasic carboxylic,
sulfonic or sulfuric acids, for example formic acid, acetic acid,
propionic acid, pivalic acid, diethylacetic acid, malonic acid,
succinic acid, pimelic acid, fumaric acid, maleic acid, lactic
acid, tartaric acid, malic acid, citric acid, gluconic acid,
ascorbic acid, nicotinic acid, isonicotinic acid, methane- or
ethanesulfonic acid, ethanedisulfonic acid, 2-hydroxyethanesulfonic
acid, benzenesulfonic acid, p-toluenesulfonic acid,
naphthalenemono- and -disulfonic acids, or laurylsulfuric acid.
Salts with physiologically unacceptable acids, for example
picrates, can be used for the isolation and/or purification of the
compounds of the formula I.
[0505] The invention furthermore relates to pharmaceutical
formulations comprising at least one compound of the formula I
and/or one of its physiologically acceptable salts and at least one
antithrombotic, a calcium antagonist or at least one prostaglandin
or prostaglandin derivative, and comprising one or more excipients
and/or assistants.
[0506] The pharmaceutical preparations are prepared, in particular,
by non-chemical methods. The active ingredients are converted into
a suitable dosage form here together with at least one solid,
liquid and/or semi-liquid excipient or assistant.
[0507] These preparations can be used as medicaments in human or
veterinary medicine. Suitable excipients are organic or inorganic
substances which are suitable for enteral (for example oral),
parenteral or topical administration and do no react with the novel
compounds, for example water, vegetable oils, benzyl alcohols,
alkylene glycols, polyethylene glycols, glycerol triacetate,
gelatine, carbohydrates, such as lactose or starch, magnesium
stearates, talc or vaseline. Suitable for oral administration are,
in particular, tablets, pills, coated tablets, capsules, powders,
granules, syrups, juices or drops, suitable for rectal
administration are suppositories, suitable for parenteral
administration are solutions, preferably oil-based or aqueous
solutions, furthermore suspensions, emulsions or implants, and
suitable for topical application are ointments, creams or powders.
The novel compounds may also be lyophilised and the resultant
lyophilisates used, for example, for the preparation of injection
preparations. The preparations indicated may be sterilised and/or
comprise assistants, such as lubricants, preservatives, stabilisers
and/or wetting agents, emulsifiers, salts for modifying the osmotic
pressure, buffer substances, colorants and flavours and/or a
plurality of further active ingredients, for example one or more
vitamins. They can furthermore be administered as nasal sprays.
[0508] In general, the substances are preferably administered in
doses of between about 1 and 500 mg, in particular between 5 and
100 mg per dosage unit. The daily dose is preferably between about
0.02 and 10 mg/kg of body weight. However, the specific dose for
each patient depends on a wide variety of factors, for example on
the efficacy of the specific compound employed, on the age, body
weight, general state of health, sex, on the diet, on the time and
method of administration, on the excretion rate, medicament
combination and severity of the particular illness to which the
therapy applies. Oral administration is preferred.
[0509] The invention therefore also relates to the use of the
pharmaceutical preparations described for the preparation of a
medicament for the treatment of angina, high blood pressure,
pulmonary hypertension, congestive heart failure (CHF), chronic
obstructive pulmonary disease (COPD), cor pulmonale, dextrocardiac
insufficiency, atherosclerosis, conditions of reduced patency of
heart vessels, peripheral vascular diseases, strokes, bronchitis,
allergic asthma, chronic asthma, allergic rhinitis, glaucoma,
irritable bowel syndrome, tumours, renal insufficiency, liver
cirrhosis and for the treatment of female sexual disorders.
[0510] The invention relates in particular to the use of the
formulations according to the invention for the preparation of a
medicament for the treatment of pulmonary hypertension, congestive
heart failure (CHF), chronic obstructive pulmonary disease (COPD),
cor pulmonale and/or dextrocardiac insufficiency.
[0511] The constituents of the novel pharmaceutical preparation are
preferably administered in combination. However, they can also be
administered individually at the same time or successively.
[0512] The invention also relates to a set (kit) consisting of
separate packs of
[0513] (a) an effective amount of
[7-(3-chloro-4-methoxybenzylamino)-1-met-
hyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-ylmethoxy]acetic acid,
ethanolamine salt, and
[0514] (b) an effective amount of an antithrombotic.
[0515] The set comprises suitable containers, such as boxes,
individual bottles, bags or ampoules. The set may, for example,
comprise separate ampoules each containing an effective amount of
[7-(3-chloro-4-methoxy-be-
nzylamino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-ylmethoxy]aceti-
c acid, ethanolamine salt, and of the antithrombotic in dissolved
or lyophilised form.
[0516] The invention furthermore relates to the use of
[7-(3-chloro-4-methoxy-benzylamino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]p-
yrimidin-5-ylmethoxy]acetic acid, ethanolamine salt, for the
preparation of a medicament for the treatment of pulmonary
hypertension, congestive heart failure (CHF), chronic obstructive
pulmonary disease (COPD), cor pulmonale and/or dextrocardiac
insufficiency
[0517] The invention also relates to a set (kit) consisting of
separate packs of
[0518] (a) an effective amount of
[7-(3-chloro-4-methoxybenzylamino)-1-met-
hyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-ylmethoxy]acetic acid,
ethanolamine salt, and
[0519] (b) an effective amount of a calcium antagonist.
[0520] The set comprises suitable containers, such as boxes,
individual bottles, bags or ampoules. The set may, for example,
comprise separate ampoules each containing an effective amount of
of
[7-(3-chloro-4-methoxybenzylamino)1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyr-
imidin-5-ylmethoxy]acetic acid, ethanolamine salt, and of the
calcium antagonist in dissolved or lyophilised form.
[0521] The invention also relates to a set (kit) consisting of
separate packs of
[0522] (a) an effective amount of
[7-(3-chloro-4-methoxybenzylamino)-1-met-
hyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-ylmethoxy]acetic acid,
ethanolamine salt, and
[0523] (b) an effective amount of a prostaglandin or prostaglandin
derivative.
[0524] The set comprises suitable containers, such as boxes,
individual bottles, bags or ampoules. The set may, for example,
comprise separate ampoules each containing an effective amount of
of
[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]py-
rimidin-5-ylmethoxy]acetic acid, ethanolamine salt, and of the
prostaglandin or prostaglandin derivative in dissolved or
lyophilised form.
[0525] Above and below, all temperatures are given in .degree. C.
In the following examples, "conventional work-up" means that water
is added if necessary, a pH of between 2 and 10, depending on the
constitution of the final product, is established if necessary, the
mixture is extracted with ethyl acetate or dichloromethane, the
phases are separated, the organic phase is dried over sodium
sulfate and evaporated, and the product is purified by
chromatography on silica gel and/or by crystallisation.
[0526] Mass spectrometry (MS): El (electron impact ionisation)
M.sup.+
[0527] FAB (fast atom bombardment) (M+H).sup.+
EXAMPLE 1
[0528] 3 g of methyl
3-[7-chloro-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrim-
idin-5-yl]propionate and 1.9 g of 3-chloro-4-methoxybenzylamine
("A") in 50 ml of dimethylformamide (DMF) are stirred at 60.degree.
for 12 hours in the presence of potassium carbonate. After
filtration, the solvent is removed, and the mixture is subjected to
conventional work-up, giving 4.6 g of methyl
3-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1H-pyr-
azolo[4,3-d]-pyrimidin-5-yl]propionate as a colourless oil.
[0529] Analogous Reaction of "A"
[0530] with methyl
2-[7-chloro-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimid-
in-5-yl]-acetate gives
[0531] methyl
2-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1H-py-
razolo[4,3-d]pyrimidin-5-yl]acetate.
[0532] Analogous Reaction of 3,4-methylenedioxybenzylamine
[0533] with methyl
3-[7-chloro-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimid-
in-5-yl]propionate gives
[0534] methyl
3-[7-(3,4-methylenedioxybenzylamino)-1-methyl-3-propyl-1H-py-
razolo[4,3-d]pyrimidin-5-yl]propionate.
[0535] Analogous Reaction of "A"
[0536] with methyl
4-[7-chloro-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimid-
in-5-yl]butyrate gives
[0537] methyl
4-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1H-py-
razolo[4,3-d]pyrimidin-5-yl]butyrate.
[0538] Analogous Reaction of 3,4-methylenedioxybenzylamine
[0539] with methyl
4-[7-chloro-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimid-
in-5-yl]butyrate gives
[0540] methyl
4-[7-(3,4-methylenedioxybenzylamino)-1-methyl-3-propyl-1H-py-
razolo[4,3-d]pyrimidin-5-yl]butyrate.
[0541] Analogous Reaction of "A"
[0542] with methyl
5-[7-chloro-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimid-
in-5-yl]valerate gives
[0543] methyl
5-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1H-py-
razolo[4,3-d]pyrimidin-5-yl]valerate.
[0544] Analogous Reaction of 3,4-methylenedioxybenzylamine
[0545] with methyl
5-[7-chloro-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimid-
in-5-yl]valerate gives
[0546] methyl
5-[7-(3,4-methylenedioxybenzylamino)-1-methyl-3-propyl-1H-py-
razolo[4,3-d]pyrimidin-5-yl]valerate.
[0547] Analogous Reaction of "A"
[0548] with methyl
7-[7-chloro-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimid-
in-5-yl]heptanoate gives
[0549] methyl
7-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1H-py-
razolo[4,3-d]pyrimidin-5-yl]heptanoate.
[0550] Analogous reaction of 3,4-methylenedioxybenzylamine with
methyl
7-[7-chloro-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]heptanoate
gives
[0551] methyl
7-[7-(3,4-methylenedioxybenzylamino)-1-methyl-3-propyl-1H-py-
razolo[4,3-d]pyrimidin-5-yl]heptanoate.
[0552] Analogous Reaction of "A"
[0553] with methyl
2-[4-(7-chloro-1-methyl-3-propyl-1H-pyrazolo[4,3-d]-pyr-
imidin-5-yl)-cyclohex-1-yl]acetate gives
[0554] methyl
2-{4-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1H-
-pyrazolo[4,3-d]pyrimidin-5-yl]-cyclohexyl-1-yl}acetate.
[0555] Analogous Reaction of 3,4-methylenedioxybenzylamine
[0556] with methyl
2-[4-(7-chloro-1-methyl-3-propyl-1H-pyrazolo[4,3-d]-pyr-
imidin-5-yl)-cyclohex-1-yl]acetate gives
[0557] methyl
2-{4-[7-(3,4-methylenedioxybenzylamino)-1-methyl-3-propyl-1H-
-pyrazolo[4,3-d]pyrimidin-5-yl]-cyclohexyl-1-yl}acetate.
[0558] Analogous Reaction of Benzylamine
[0559] with methyl
3-[7-chloro-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimid-
in-5-yl]propionate gives
[0560] methyl
3-[7-benzylamino-1-methyl-3-propyl-1H-pyrazolo[4,3-d]-pyrimi-
din-5-yl]propionate;
[0561] with methyl
4-[7-chloro-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimid-
in-5-yl]butyrate gives
[0562] methyl
4-[7benzylamino-1-methyl-3-propyl-1H-pyrazolo[4,3-d]-pyrimid-
in-5-yl]butyrate;
[0563] with methyl
5-[7-chloro-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimid-
in-5-yl]valerate gives
[0564] methyl
5-[7benzylamino-1-methyl-3-propyl-1H-pyrazolo[4,3-d]-pyrimid-
in-5-yl]valerate.
[0565] Analogous Reaction of "A"
[0566] with methyl
4-[7-chloro-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimid-
in-5-yl]cyclohexanecarboxylate gives
[0567] methyl
4-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1H-py-
razolo[4,3-d]pyrimidin-5-yl]cyclohexanecarboxylate and reaction of
3,4-methylenedioxybenzylamine gives
[0568] methyl
4-[7-(3,4-methylendioxybenzylamino)-1-methyl-3-propyl-1H-pyr-
azolo[4,3-d]pyrimidin-5-yl]cyclohexanecarboxylate.
EXAMPLE 2
[0569] 4.3 g of methyl
3-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-pro-
pyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]propionate are dissolved in 30
ml of tetrahydrofuran (THF), 10 ml of 10% NaOH are added, and the
mixture is stirred at 60.degree. for 8 hours. After 10% HCl has
been added, the deposited crystals are separated off and
recrystallised from methanol, giving 3.7 g of
3-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1H-
-pyrazolo-[4,3-d]pyrimidin-5-yl]propionic acid, m.p.
178.degree..
[0570] Evaporation with the equivalent amount of methanolic
potassium hydroxide solution gives the potassium salt of the acid
as an amorphous powder.
[0571] Analogous reaction of the esters listed in Example 1 gives
the compounds
[0572]
2-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo[-
4,3-d]pyrimidin-5-yl]acetic acid,
[0573]
3-[7-(3,4-methylenedioxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo[-
4,3-d]pyrimidin-5-yl]propionic acid,
[0574]
4-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo[-
4,3-d]pyrimidin-5-yl]butyric acid, m.p. 152.degree.;
[0575]
4-[7-(3,4-methylenedioxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo[-
4,3-d]pyrimidin-5-yl]butyric acid, m.p. 172.degree.;
[0576]
5-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo[-
4,3-d]pyrimidin-5-yl]valeric acid, m.p. 159.degree.;
[0577]
5-[7-(3,4-methylenedioxybenzylamino)1-methyl-3-propyl-1H-pyrazolo[4-
,3-d]pyrimidin-5-yl]valeric acid, ethanolamine salt, m.p.
160.degree.;
[0578]
7-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo[-
4,3-d]pyrimidin-5-yl]heptanoic acid,
[0579]
7-[7-(3,4-methylenedioxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo[-
4,3-d]pyrimidin-5-yl]heptanoic acid,
[0580]
2-{4-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1H-pyrazo-
lo[4,3-d]pyrimidin-5-yl]cyclohexyl-1-yl}acetic acid,
[0581]
2-{4-[7-(3,4-methylenedioxybenzylamino)-1-methyl-3-propyl-1H-pyrazo-
lo[4,3-d]pyrimidin-5-yl]cyclohexyl-1-yl}acetic acid,
[0582]
3-[7benzylamino-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-
-propionic acid,
[0583]
4-[7benzylamino-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-
-butyric acid,
[0584]
5-[7benzylamino-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-
-valeric acid, m.p. 185.degree.;
[0585]
4-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo[-
4,3-d]pyrimidin-5-yl]cyclohexanecarboxylic acid,
[0586]
4-[7-(3,4-methylenedioxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo[-
4,3-d]pyrimidin-5-yl]cyclohexanecarboxylic acid.
[0587] An analogous reaction gives the compounds
[0588]
5-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-isopropyl-1H-pyrazo-
lo[4,3-d]pyrimidin-5-yl]valeric acid, cyclohexylamine salt, m.p.
148.degree.;
[0589]
4-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-ethyl-1H-pyrazolo[4-
,3-d]pyrimidin-5-yl]butyric acid, m.p. 176.degree.;
[0590]
4-[7-(3,4-methylenedioxybenzylamino)-1-methyl-3-ethyl-1H-pyrazolo[4-
,3-d]pyrimidin-5-yl]butyric acid, m.p. 187.degree.;
[0591]
4-[7-(3-chloro-4-methoxybenzylamino)-1-ethyl-3-methyl-1H-pyrazolo[4-
,3-d]pyrimidin-5-yl]butyric acid, m.p. 206.degree.;
[0592]
4-[7-(3,4-methylenedioxybenzylamino)-1-ethyl-3-methyl-1H-pyrazolo[4-
,3-d]pyrimidin-5-yl]butyric acid, m.p. 177.degree.;
[0593]
4-[7benzylamino-1-methyl-3-ethyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]--
butyric acid, m.p. 208.degree.;
[0594]
4-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-methyl-1H-pyrazolo[-
4,3-d]pyrimidin-5-yl]butyric acid, m.p. 250.degree.;
[0595]
4-[7-(3,4-methylenedioxybenzylamino)-1-methyl-3-methyl-1H-pyrazolo[-
4,3-d]pyrimidin-5-yl]butyric acid, m.p. 225.degree.;
[0596]
4-[7benzylamino-1-methyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-
-butyric acid, m.p. 201.degree.;
[0597]
5-[7-(4-Methoxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]-py-
rimidin-5-yl]valeric acid, m.p. 160.degree.;
[0598]
5-[7-(3-Methoxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]-py-
rimidin-5-yl]valeric acid, m.p. 141.degree.;
[0599]
5-[7-(4-chlorobenzylamino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]-pyr-
imidin-5-yl]valeric acid, m.p. 148.degree.;
[0600]
5-[7-(3-chlorobenzylamino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]-pyr-
imidin-5-yl]valeric acid, m.p. 151.degree.;
EXAMPLE 3
[0601] A mixture of 1.8 g of methyl
4-[7-chloro-1-methyl-3-propyl-1H-pyraz-
olo-[4,3-d]pyrimidin-5-yl]phenylcarboxylate ("B") and 1.5 g of
3-chloro-4-methoxybenzylamine in 20 ml of N-methylpyrrolidone is
heated at 110.degree. for 4 hours. After cooling, the mixture is
subjected to conventional work-up, giving 2.2 g of methyl
4-[7-(3-chloro-4-methoxybenz-
ylamino1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]benzoate.
[0602] Analogously to Example 2, 1.2 g of the ester give 1.0 g
of
[0603]
4-[7-(3-chloro-4-methoxybenzylamino1-methyl-3-propyl-1H-pyrazolo[4,-
3-d]pyrimidin-5-yl]benzoic acid, ethanolamine salt, m.p.
139.degree..
[0604] Analogously to Example 1, "B" and
3,4-methylenedioxybenzylamine give
[0605] methyl
4-[7-(3,4-methylenedioxybenzylamino)-1-methyl-3-propyl-1H-py-
razolo[4,3-d]pyrimidin-5-yl]benzoate, and ester hydrolysis thereof
gives
[0606]
4-[7-(3,4-methylenedioxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo[-
4,3-d]pyrimidin-5-yl]benzoic acid.
[0607] An analogous reaction gives the compound
[0608]
4-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo[-
4,3-d]pyrimidin-5-yl]-phenylessigsure, glucamine salt, m.p.
114.degree. and
[0609]
4-[7-(3,4-methylenedioxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo[-
4,3-d]pyrimidin-5-yl]phenyl acetic acid.
EXAMPLE 4
[0610] 1 equivalent of
3-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-pro-
pyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]propionic acid and 1.2
equivalents of thionyl chloride are stirred in dichloromethane for
2 hours. The solvent is removed, giving
3-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-
-1H-pyrazolo[4,3-d]pyrimidin-5-yl]propionyl chloride.
[0611] The product is transferred into aqueous ammonia, and the
mixture is stirred for one hour and subjected to conventional
work-up, giving
3-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]-
-pyrimidin-5-yl]propionamide.
EXAMPLE 5
[0612] 1 equivalent of DMF and 1 equivalent of oxalyl chloride are
dissolved in acetonitrile at 0.degree.. 1 equivalent of
3-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1
H-pyrazolo[4,3-d]pyrimidin-5-yl]propionamide is then added. The
mixture is stirred for one hour. Conventional work-up gives
3-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]-
-pyrimidin-5-yl]-propionitrile.
EXAMPLE 6
[0613] Reaction of the corresponding chloro-pyrimidine derivates
with 3,4-ethylenedioxybenzylamine analogously to Examples 1, 2 and
3 gives the following carboxylic acids
[0614]
4-[7-(3,4-ethylenedioxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo-[-
4,3-d]pyrimidin-5-yl]butyric acid,
[0615]
3-[7-(3,4-ethylenedioxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo-[-
4,3-d]pyrimidin-5-yl]propionic acid,
[0616]
5-[7-(3,4-ethylenedioxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo-[-
4,3-d]pyrimidin-5-yl]valeric acid,
[0617]
7-[7-(3,4-ethylenedioxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo-[-
4,3-d]pyrimidin-5-yl]heptanoic acid,
[0618]
2-{4-[7-(3,4-ethylenedioxybenzylamino)-1-methyl-3-propyl-1H-pyrazol-
o[4,3-d]pyrimidin-5-yl]cyclohexyl-1-yl}acetic acid,
[0619]
4-[7-(3,4-ethylenedioxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo-[-
4,3-d]pyrimidin-5-yl]cyclohexanecarboxylic acid,
[0620]
4-[7-(3,4-ethylenedioxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo-[-
4,3-d]pyrimidin-5-yl]benzoic acid,
[0621]
4-[7-(3,4-ethylenedioxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo-[-
4,3-d]pyrimidin-5-yl]benzoic acid,
[0622]
4-[7-(3,4-ethylenedioxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo-[-
4,3-d]pyrimidin-5-yl]phenylacetic acid.
[0623] Analogous reaction with 3,4-dichlorobenzylamine gives the
following compounds
[0624]
4-[7-(3,4-dichlorobenzylamino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]-
-pyrimidin-5-yl]butyric acid, m.p. 209.degree.;
[0625]
3-[7-(3,4-dichlorobenzylamino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]-
-pyrimidin-5-yl]propionic acid,
[0626]
5-[7-(3,4-dichlorobenzylamino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]-
-pyrimidin-5-yl]valeric acid,
[0627]
7-[7-(3,4-dichlorobenzylamino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]-
-pyrimidin-5-yl]heptanoic acid,
[0628]
2-{4-[7-(3,4-dichlorobenzylamino)-1-methyl-3-propyl-1H-pyrazolo-[4,-
3-d]pyrimidin-5-yl]cyclohexyl-1-yl}acetic acid,
[0629]
4-[7-(3,4-dichlorobenzylamino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]-
-pyrimidin-5-yl]cyclohexanecarboxylic acid,
[0630]
4-[7-(3,4-dichlorobenzylamino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]-
-pyrimidin-5-yl]benzoic acid,
[0631]
4-[7-(3,4-dichlorobenzylamino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]-
-pyrimidin-5-yl]phenylacetic acid.
[0632] Analogous reaction with 3-chloro-4-ethoxybenzylamine gives
the following compounds
[0633]
4-[7-(3-chloro-4-ethoxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo-[-
4,3-d]pyrimidin-5-yl]butyric acid,
[0634]
3-[7-(3-chloro-4-ethoxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo-[-
4,3-d]pyrimidin-5-yl]propionic acid,
[0635]
5-[7-(3-chloro-4-ethoxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo-[-
4,3-d]pyrimidin-5-yl]valeric acid,
[0636]
7-[7-(3-chloro-4-ethoxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo-[-
4,3-d]pyrimidin-5-yl]heptanoic acid,
[0637]
2-{4-[7-(3-chloro-4-ethoxybenzylamino)-1-methyl-3-propyl-1H-pyrazol-
o[4,3-d]pyrimidin-5-yl]cyclohexyl-1-yl}acetic acid,
[0638]
4-[7-(3-chloro-4-ethoxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo-[-
4,3-d]pyrimidin-5-yl]cyclohexanecarboxylic acid,
[0639]
4-[7-(3-chloro-4-ethoxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo-[-
4,3-d]pyrimidin-5-yl]benzoic acid,
[0640]
4-[7-(3-chloro-4-ethoxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo[4-
,3-d]pyrimidin-5-yl]phenylacetic acid.
[0641] Analogous reaction with 3-chloro-4-isopropoxybenzylamine
gives the following compounds
[0642]
4-[7-(3-chloro-4-isopropoxybenzylamino)-1-methyl-3-propyl-1H-pyrazo-
lo[4,3-d]pyrimidin-5-yl]butyric acid,
[0643]
3-[7-(3-chloro-4-isopropoxybenzylamino)-1-methyl-3-propyl-1H-pyrazo-
lo[4,3-d]pyrimidin-5-yl]propionic acid,
[0644]
5-[7-(3-chloro-4-isopropoxybenzylamino)-1-methyl-3-propyl-1H-pyrazo-
lo[4,3-d]pyrimidin-5-yl]valeric acid,
[0645]
7-[7-(3-chloro-4-isopropoxybenzylamino)-1-methyl-3-propyl-1H-pyrazo-
lo[4,3-d]pyrimidin-5-yl]heptanoic acid,
[0646]
2-{4-[7-(3-chloro-4-isopropoxybenzylamino)-1-methyl-3-propyl-1H-pyr-
azolo[4,3-d]pyrimidin-5-yl]cyclohexyl-1-yl}acetic acid,
[0647]
4-[7-(3-chloro-4-isopropoxybenzylamino)-1-methyl-3-propyl-1H-pyrazo-
lo[4,3-d]pyrimidin-5-yl]cyclohexanecarboxylic acid,
[0648]
4-[7-(3-chloro-4-isopropoxybenzylamino)-1-methyl-3-propyl-1H-pyrazo-
lo[4,3-d]pyrimidin-5-yl]benzoic acid,
[0649]
4-[7.-(3-chloro-4-isopropoxybenzylamino)-1-methyl-3-propyl-1H-pyraz-
olo[4,3-d]pyrimidin-5-yl]phenylacetic acid.
EXAMPLE 7
[0650] An analogous reaction to Examples 1 and 2 gives the
compound
[0651]
[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1H-pyrazolo[4,-
3-d]-pyrimidin-5-ylmethoxy]acetic acid, ethanolamine salt, m.p.
138.degree..
[0652] The examples below relate to pharmaceutical
preparations:
EXAMPLE A: INJECTION VIALS
[0653] A solution of 100 g of an active ingredient of the formula
I, 100 g of the antithrombotic and 5 g of disodium
hydrogenphosphate in 3 l of bidistilled water is adjusted to pH 6.5
using 2N hydrochloric acid, sterile filtered, transferred into
injection vials, lyophilised under sterile conditions and sealed
under sterile conditions. Each injection vial contains 5 mg of each
active ingredient.
EXAMPLE B: SUPPOSITORIES
[0654] A mixture of 20 g of an active ingredient of the formula I,
20 g of an antithrombotic with 100 g of soya lecithin and 1400 g of
cocoa butter is melted, poured into moulds and allowed to cool.
Each suppository contains 20 mg of each active ingredient.
EXAMPLE C: SOLUTION
[0655] A solution is prepared from 1 g of an active ingredient of
the formula I, 1 g of an antithrombotic, 9.38 g of
NaH.sub.2PO.sub.4.2H.sub.2- O, 28.48 g of
Na.sub.2HPO.sub.4.12H.sub.2O and 0.1 g of benzalkonium chloride in
940 ml of bidistilled water. The pH is adjusted to 6.8, and the
solution is made up to 1 l and sterilised by irradiation. This
solution can be used in the form of eye drops.
EXAMPLE D: OINTMENT
[0656] 500 mg of an active ingredient of the formula I and 500 mg
of an antithrombotic are mixed with 99.5 g of Vaseline under
aseptic conditions.
EXAMPLE E: TABLETS
[0657] A mixture of 1 kg of an active ingredient of the formula I,
1 kg of an antithrombotic, 4 kg of lactose, 1.2 kg of potato
starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is pressed
to give tablets in a conventional manner in such a way that each
tablet contains 10 mg of each active ingredient.
EXAMPLE F: COATED TABLETS
[0658] Tablets are pressed analogously to Example E and
subsequently coated in a conventional manner with a coating of
sucrose, potato starch, talc, tragacanth and dye.
EXAMPLE G: CAPSULES
[0659] 2 kg of an active ingredient of the formula I and 2 kg of an
antithrombotic are introduced into hard gelatine capsules in a
conventional manner in such a way that each capsule contains 20 mg
of each active ingredient.
EXAMPLE H: AMPOULES
[0660] A solution of 1 kg of an active ingredient of the formula I
and 1 kg of an antithrombotic in 60 l of bidistilled water is
sterile filtered, transferred into ampoules, lyophilised under
sterile conditions and sealed under sterile conditions. Each
ampoule contains 10 mg of each active ingredient.
EXAMPLE I: INHALATION SPRAY
[0661] 14 g of an active ingredient of the formula I and 14 g of an
antithrombotic are dissolved in 10 l of isotonic NaCl solution, and
the solution is transferred into commercially available spray
containers with a pump mechanism. The solution can be sprayed into
the mouth or nose. One spray shot (about 0.1 ml) corresponds to a
dose of about 0.14 mg of each active ingredient.
EXAMPLE A': INJECTION VIALS
[0662] A solution of 100 g of an active ingredient of the formula
I, 100 g of the calcium antagonist and 5 g of disodium
hydrogenphosphate in 3 l of bidistilled water is adjusted to pH 6.5
using 2N hydrochloric acid, sterile filtered, transferred into
injection vials, lyophilised under sterile conditions and sealed
under sterile conditions. Each injection vial contains 5 mg of each
active ingredient.
EXAMPLE B': SUPPOSITORIES
[0663] A mixture of 20 g of an active ingredient of the formula I,
20 g of a calcium antagonist with 100 g of soya lecithin and 1400 g
of cocoa butter is melted, poured into moulds and allowed to cool.
Each suppository contains 20 mg of each active ingredient.
EXAMPLE C': SOLUTION
[0664] A solution is prepared from 1 g of an active ingredient of
the formula I, 1 g of a calcium antagonist, 9.38 g of
NaH.sub.2PO.sub.4.2H.su- b.2O, 28.48 g of
Na.sub.2HPO.sub.4.12H.sub.2O and 0.1 g of benzalkonium chloride in
940 ml of bidistilled water. The pH is adjusted to 6.8, and the
solution is made up to 1 l and sterilised by irradiation. This
solution can be used in the form of eye drops.
EXAMPLE D': OINTMENT 500 mg of an active ingredient of the formula
I and 500 mg of a calcium antagonist are mixed with 99.5 g of
Vaseline under aseptic conditions.
EXAMPLE E': TABLETS
[0665] A mixture of 1 kg of an active ingredient of the formula I,
1 kg of a calcium antagonist, 4 kg of lactose, 1.2 kg of potato
starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is pressed
to give tablets in a conventional manner in such a way that each
tablet contains 10 mg of each active ingredient.
EXAMPLE F': COATED tabl ts
[0666] Tablets are pressed analogously to Example E and
subsequently coated in a conventional manner with a coating of
sucrose, potato starch, talc, tragacanth and dye.
EXAMPLE G': CAPSULES
[0667] 2 kg of an active ingredient of the formula I and 2 kg of a
calcium antagonist are introduced into hard gelatine capsules in a
conventional manner in such a way that each capsule contains 20 mg
of each active ingredient.
EXAMPLE H': AMPOULES
[0668] A solution of 1 kg of an active ingredient of the formula I
and 1 kg of a calcium antagonist in 60 l of bidistilled water is
sterile filtered, transferred into ampoules, lyophilised under
sterile conditions and sealed under sterile conditions. Each
ampoule contains 10 mg of each active ingredient.
EXAMPLE I': INHALATION SPRAY
[0669] 14 g of an active ingredient of the formula I and 14 g of a
calcium antagonist are dissolved in 10 l of isotonic NaCl solution,
and the solution is transferred into commercially available spray
containers with a pump mechanism. The solution can be sprayed into
the mouth or nose. One spray shot (about 0.1 ml) corresponds to a
dose of about 0.14 mg of each active ingredient.
EXAMPLE A": INJECTION VIALS
[0670] A solution of 100 g of an active ingredient of the formula
I, 100 g of the prostaglandin or prostaglandin derivative and 5 g
of disodium hydrogen-phosphate in 3 l of bidistilled water is
adjusted to pH 6.5 using 2N hydrochloric acid, sterile filtered,
transferred into injection vials, lyophilised under sterile
conditions and sealed under sterile conditions. Each injection vial
contains 5 mg of each active ingredient.
EXAMPLE B": SUPPOSITORI s
[0671] A mixture of 20 g of an active ingredient of the formula I,
20 g of a prostaglandin or prostaglandin derivative with 100 g of
soya lecithin and 1400 g of cocoa butter is melted, poured into
moulds and allowed to cool. Each suppository contains 20 mg of each
active ingredient.
EXAMPLE C": SOLUTION
[0672] A solution is prepared from 1 g of an active ingredient of
the formula I, 1 g of a prostaglandin or prostaglandin derivative,
9.38 g of NaH.sub.2PO.sub.4.2H.sub.2O, 28.48 g of
Na.sub.2HPO.sub.4.12H.sub.2O and 0.1 g of benzalkonium chloride in
940 ml of bidistilled water. The pH is adjusted to 6.8, and the
solution is made up to 1 l and sterilised by irradiation. This
solution can be used in the form of eye drops.
EXAMPLE D": OINTMENT
[0673] 500 mg of an active ingredient of the formula I and 500 mg
of a prostaglandin or prostaglandin derivative are mixed with 99.5
g of Vaseline under aseptic conditions.
EXAMPLE E": TABLETS
[0674] A mixture of 1 kg of an active ingredient of the formula I,
1 kg of a prostaglandin or prostaglandin derivative, 4 kg of
lactose, 1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of
magnesium stearate is pressed to give tablets in a conventional
manner in such a way that each tablet contains 10 mg of each active
ingredient.
EXAMPLE F": COATED TABLETS
[0675] Tablets are pressed analogously to Example E and
subsequently coated in a conventional manner with a coating of
sucrose, potato starch, talc, tragacanth and dye.
EXAMPL G": CAPSULES
[0676] 2 kg of an active ingredient of the formula I and 2 kg of a
prostaglandin or prostaglandin derivative are introduced into hard
gelatine capsules in a conventional manner in such a way that each
capsule contains 20 mg of each active ingredient.
EXAMPLE H": AMPOULES
[0677] A solution of 1 kg of an active ingredient of the formula I
and 1 kg of a prostaglandin or prostaglandin derivative in 60 l of
bidistilled water is sterile filtered, transferred into ampoules,
lyophilised under sterile conditions and sealed under sterile
conditions. Each ampoule contains 10 mg of each active
ingredient.
EXAMPLE I": INHALATION SPRAY
[0678] 14 g of an active ingredient of the formula I and 14 g of a
prostaglandin or prostaglandin derivative are dissolved in 10 l of
isotonic NaCl solution, and the solution is transferred into
commercially available spray containers with a pump mechanism. The
solution can be sprayed into the mouth or nose. One spray shot
(about 0.1 ml) corresponds to a dose of about 0.14-mg of each
active ingredient.
* * * * *